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ABSTRACT 
High-throughput screening (HTS) represents a powerful tool for drug discovery 
by allowing 104 to 105 assays to be completed within a single day. Typically, assays are 
performed in multiwell plates (MWPs) utilizing fluorogenic substrates for detection. 
These substrates increase development time and can introduce artifactual results. 
Therefore, alternate screening strategies based around natural substrates are necessary. 
 We developed a screening platform that couples nanoliter volume samples to 
microchip electrophoresis for analysis using a novel polydimethylsiloxane (PDMS)-and-
glass microfluidic device. The system was demonstrated by screening a small library 
against protein kinase A (PKA), which regulates metabolism within the cell. It was 
chosen for its well-characterized kinetic parameters and commercially available peptide 
substrates. Sample throughput of 0.16 Hz was achieved allowing at least 6 replicate MCE 
injections from each sample in a high quality assay (Z’-factor = 0.8). 
 To demonstrate the ability to screen larger libraries, we developed a novel assay 
for sirtuin 5 (SIRT5) using a naturally derived peptide substrate. SIRT5 impacts 
metabolism and has reported oncogenic functions making inhibitor identification of 
clinical importance. Compared to the PKA assay previously developed, assay throughput 
was increased 3-fold and 1406 samples were analyzed within 46 minutes (0.5 Hz). Using 
a 250 ms separation, each assay sample could be analyzed 8 times by MCE generating 
  xviii 
over 11,000 electropherograms. Several previously unreported inhibitors of SIRT5 were 
identified and verified by dose-response analysis.  
 Finally, work toward miniaturization of high-throughput assays was demonstrated 
by performing sample preparation and analysis completely within nanoliter volume 
droplets. A simple to use and easy to fabricate PDMS microfluidic device was developed 
to allow addition of assay reagents to nanoliter volume samples. Reagent use, relative to 
assays performed in 384 well plates, could be reduced 1,000-fold and sample-to-sample 
carryover was less than 5 percent under typical experimental conditions. Analysis of 
samples prepared in droplet format was demonstrated with droplets containing a 
fluorescent dye and addition of a fluorescent peptide. These samples could be analyzed 
by MCE at 0.33 samples per second but increased throughput should be possible by using 
higher flow rates.  
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CHAPTER 1:  INTRODUCTION 
High-Throughput Screening 
High-throughput screening (HTS) has emerged in recent years as a powerful tool 
in drug discovery and other areas of biology and chemistry, such as catalyst discovery 
and protein engineering.1, 2 High-throughput workflows are able to assay 104 to 105 
compounds against a selected target within a single day. To achieve this level of 
throughput, most HTS utilizes multi-well plate (MWP)-based assays with robotic plate 
manipulation and liquid handling to massively parallelize sample preparation.1-5 With the 
increasing size of compound libraries available, MWP density has increased from 96 to 
1536 wells per plate in an effort to reduce assay time and sample consumption. Many 
technologies exist for high-throughput sample preparation ranging from bulk liquid 
dispensing (i.e. Thermo Fisher MultiDrop Combi) to compound library dispensing at 
nanoliter volumes (i.e. Caliper Life Science SciClone pin tool). These technologies allow 
even large compound libraries to be prepared in a timely manner. 
Drug discovery has largely focused on five target families: G protein coupled 
receptors, kinases, proteases, nuclear receptors, and ion channels.6 However, these 
families miss a large number of pharmacological targets within cells, such as other 
enzyme classes. Enzymes, which include kinases and proteases, efficiently catalyze 
chemical reactions to regulate cellular functions, such as metabolism, cell death, and 
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protein degradation. Indeed, many diseases and disorders have been linked to over- or 
under-expression of specific enzymes demonstrating their importance as pharmacological 
targets for disease intervention. Emphasizing this point, 50 percent of drugs on the 
market as of 2006 targeted enzymes (i.e. proteases and kinases).7 
To achieve the throughput necessary for drug discovery, most assays utilize 
fluorescence detection methods. These tend to be robust, useful in homogenous assays 
found in HTS, and compatible with the small sample volumes associated with high-
density well plates. To measure the effect of test compounds, a loss or gain of signal must 
be correlated to enzyme activity.  For example, to detect β-galactosidase activity 
fluorescein-di-β-D-galactopyranoside (FDG), which consists of a fluorescein molecule 
conjugated to two galactopyranosyl moieties, is commonly used.8 In the absence of β-
galactosidase the substrates is non-fluorescent; however, removal of the galactopyranosyl 
moieties by the enzyme results in a fluorescent signal that correlates the β-galactosidase 
activity. Alternatively, coupled enzyme cascades, such as the commonly used Amplex 
Red system, can be used if fluorogenic substrates are unavailable. These assays 
stoichiometrically couple product formation in an assay of interest to a formation of a 
fluorescent product through a series of secondary enzymes. In many cases, this requires 
the development of novel fluorogenic substrates or optimization of coupled enzyme 
reactions for each assay9 increasing assay development time and cost. Additionally, use 
of artificial substrates has the potential to generate false positive results due to possible 
non-physiological behaviors of the engineered substrates. To address these and other 
limitations, work has been done to develop HTS assays based on alternative detection 
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modes, such as liquid chromatography (LC), mass spectrometry (MS), surface plasmon 
resonance (SPR), and impedance, that avoid fluorogenic substrates.9-16 
Several limitations exist for applying these alternative detection strategies to high-
throughput screening. In the case of the optical assays, multi-analyte detection is difficult 
and most assays require multiple steps to generate a signal. For LC-MS assays, label-free 
analysis allows one to use natural peptides without needing to engineer a fluorophore; 
however, the throughput remains low due to slow LC separations.  
Capillary and Microchip Electrophoresis for High-Throughput Screening 
Although LC-MS methods tend to have low throughput unsuited to large-scale 
screening, other separations-based HTS methods, with potentially higher throughput, are 
possible. Capillary electrophoresis (CE), another separation technique, allows for rapid 
separation of analytes not possible by most LC-MS methods. This combined with the 
benefits of LC-MS methods, such as multi-analyte detection and spatial separation of 
interfering species, makes CE an attractive option for HTS. If fluorophores are required 
for detection, they can be placed remotely from the active peptide residue to reduce the 
likelihood of false positive results caused by non-specific interactions. Furthermore, 
peptide engineering to quench the fluorophore prior to enzymatic activity is not necessary 
because substrate and product can be separated prior to detection. To understand the 
potential of CE-based HTS, it will beneficial to discuss several fundamental aspects of 
CE and previous attempts at HTS by CE. 
First established in 1981,17 CE is typically performed fused-silica capillaries or on 
glass microfluidic devices, in which case it is called microchip electrophoresis (MCE),18, 
19 with the inlet and outlet connected to a voltage source (Figure 1-1). This development 
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addressed several limitations associated with existing electrophoretic methods (i.e. gel 
electrophoresis), such as slow separation speed and excessive joule heating. CE and MCE 
address these limitations by performing separations within narrow bore channels or tubes 
(i.e. 5-200 µm inner diameter) that afford better heat dissipation. Improved heat 
dissipation, in turn, allows application of higher voltages to achieve faster separations and 
improved performance.  
In electrophoresis, analytes migrate through an electrically conductive buffer, 
called the background electrolyte (BGE), under the influence of an applied electric field. 
The speed and direction of migration, which ultimately affects analyte separation, is 
based on a combination of the electroosmotic mobility (µEOF) contributed by the buffer 
and the electrophoretic mobility (µEP) of the analyte.  
Electroosmotic mobility is due to the formation of an electric double layer at the 
surface of the fused silica due to interactions between the negatively charged surface 
silanols and positive counter ions within the BGE (Figure 1-1, top). When an electric 
field (E) is applied, these ions move along the wall dragging the bulk solution and 
creating a net flow toward the cathode. This flow, called electroosmotic flow (EOF), 
moves with a velocity (νEOF) determined by the following equation: 
𝑣𝑣𝐸𝐸𝐸𝐸𝐸𝐸 =  µ𝐸𝐸𝐸𝐸𝐸𝐸𝐸𝐸 =  𝜀𝜀𝜀𝜀𝜂𝜂 𝐸𝐸     Eq. 1-1 
where ε is the permittivity of the BGE, ζ is the zeta-potential at the capillary wall, and 
η is the solution viscosity. This equation suggests that EOF is characteristic of the buffer 
composition and increases with applied electric field. The electrophoretic mobility is an 
intrinsic property of each analyte as is described as: 
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µ = 𝑞𝑞6𝜋𝜋𝜂𝜂𝜋𝜋      Eq. 1-2 
where q is the analyte charge and r is the Stoke’s radius of the analyte. Finally, the net 
migration velocity of each analyte (ν) will depend on contributions from both terms: 
𝜈𝜈 = (µ𝐸𝐸𝐸𝐸𝐸𝐸 + µ𝐸𝐸𝐸𝐸)𝐸𝐸     Eq. 1-3 
Therefore, analytes can be separated from one another based on their charge-to-size ratio. 
Under normal separation conditions (i.e. negatively charged surface and high pH buffers), 
EOF is directed toward the cathode (outlet), and cations migrate fastest, followed by all 
neutral compounds, and finally anions.  
 Compared to LC separations, which use pressure driven flow, EOF has a plug-
shaped profile resulting in less band broadening during the separation. Additionally, 
assuming Joule heating, injection width, and analyte adsorption are mitigated, diffusion is 
the only source of band broadening. Under these conditions, theory suggests that 
increasing separation voltage (V) allows for shorter migration times (Eq. 1-4) and higher 
efficiency (Eq. 1-5),20 where tmig is migration time, L is capillary or channel length, N is 
number of theoretical plates, and D is the analyte diffusion constant.  
𝑡𝑡𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑜𝑜𝑛𝑛 = 𝐿𝐿(µ𝐸𝐸𝐸𝐸𝐸𝐸 + µ𝐸𝐸𝐸𝐸)𝑉𝑉      Eq. 1-4 
𝑁𝑁 = (µ𝐸𝐸𝐸𝐸𝐸𝐸 + µ𝐸𝐸𝐸𝐸)𝑉𝑉2𝐷𝐷      Eq. 1-5 
As demonstrated by these equations, the separation length can be reduced to 
achieve faster separations without sacrificing efficiency by maintaining the same applied 
voltage (i.e. increasing the electric field). This is especially important for screening 
applications, in which high-throughput is essential, as it demonstrates fast and high 
quality separations are possible. 
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Figure 1-1. Schematic of capillary electrophoresis instrumentation and characteristics. 
The inlet and outlet of a fused silica capillary, filled with background electrolyte, are 
inserted into buffer vials connected to a high-voltage power supply. The external electric 
field generates an electric double layer due to interactions between the negatively charged 
surface and counter ions in the buffer (top grey box). This generates a plug-shaped 
electroosmotic flow. Analytes are separated based on differences in size-to-charge ratio 
with positive analytes migrating fastest and negatively charged analytes migrating 
slowest. All neutral analytes co-migrate with EOF. 
 Detection in CE or MCE is typically achieved through laser induced fluorescence 
(LIF), UV absorbance spectroscopy, electrochemical detection, or mass spectrometry. 
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LIF is the most common detection method due to high sensitivity and simplicity.21 Due to 
path length independence, the narrow bore of capillaries or microchannels does not limit 
detection efficiency and picomolar detection limits are possible. The primary 
disadvantage of LIF detection for high-throughput screening is the lack of natively 
fluorescent substrates and potential interactions caused by the fluorophore. 
 Because CE separates based on differences in size or charge, it is well suited to 
biochemical assay screening. The majority of enzymes induce changes on their substrate 
through removal of post-translation modifications, such as acetyl, succinyl, and 
phosphate groups, or cleavage of peptide bonds in the case of proteases. These changes in 
size and charge can be exploited to quickly separate substrate and product peptides. For 
example, SIRT1 targets the removal acetyl modifications from lysine residues. Under 
basic conditions typical of CE, the deactylated product peptide will have a higher net 
positive charge than the substrate due to exposure of the amine functional group on the 
lysine side change. This positive charge results in faster migration times for product 
peptides compared to substrate. This same idea can be exploited for monitoring protein-
protein interactions through affinity probe capillary electrophoresis (APCE). In APCE, 
one protein is fluorescently labeled while the other remains unlabeled. The migration 
time of the labeled protein will shift depending on whether it is bound to the target 
protein or unbound; in turn, this can be used to quantify the degree of interaction. An 
example was the use of CE to identify small molecule inhibitors of the interaction 
between Heat Shock Protein 70 (Hsp70) and Bcl2-associated athanogene 3 (Bag3). Over 
3000 compounds were tested, using a separation based on a combination of 
electrophoresis and pressure driven flow.22 
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 One potential challenge of using CE or MCE with LIF detection for high-
throughput screening is the effect of test compounds on migration time or analyte 
detection. In the case of migration time, test compounds could affect the electric double 
layer leading to enhanced or suppressed EOF and shifting migration times. However, 
most screening is done with compound concentrations below 20 µM and therefore should 
not have a significant impact on EOF. It is also possible that test compounds could 
fluoresce and lead to false positive results. However, deconvolution of signal from test 
compounds and substrates is possible due to the spatial separation achieved during CE or 
MCE. In conventional MWP assays, it would be impossible to screen natively fluorescent 
test compounds, as their signal would add to signal from the fluorogenic probe. 
 Although rapid separations are possible by electrophoresis, the bottleneck for 
high-throughput analysis remains sample introduction. Conventional CE or MCE systems 
use auto-samplers or manual sample dispensing to sequentially analyze samples leading 
to low sample throughput and large sample requirements. One group developed several 
small, labeled peptides based on the SIRT1 substrate, p53, for screening and 
demonstrated SIRT1 activity with several known modulators.23, 24 In another example, a 
commercial CE system was used to identify protein-protein interaction inhibitors from a 
library of 3,000 compounds at a rate of 220 compounds per day.22 In both examples, 
sample throughput was not significantly improved over typical LC-MS assays. 
A commercial microfluidics system – the LabChip system – overcomes this 
limitation through the use of a ‘sipper’ sample loading method. In this design samples are 
arrayed in a MWP, and a short length of tubing connected the microchip is dipped into a 
sample well allowing sample to be pulled into the separation channel by applied vacuum 
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(Figure 1-2). Through interfacing to a MWP, samples can be prepared using existing 
high-throughput workflows and continuous operation is possible. The system was 
demonstrated in an assay for SIRT1 in which a fluorescently labeled peptide could be 
separated within 50 seconds.25 However, this method does not achieve the potential of 
MCE-based screening because of band broadening induced by vacuum driven flow in the 
separation channel and throughput of only 0.02 samples per second. 
 
 
Figure 1-2. Schematic of the Caliper LabChip system for screening biochemical assays 
by microchip electrophoresis. At the top, shown coming in and out of the plane, is the 
microchip used for separation by a combination of electrophoresis and vacuum driven 
flow (applied at the outlet reservoir). Sample is introduced through a ‘sipper’ tube by 
interfacing to a multiwell plate. Labeled substrate and product peptides are separated 
based on differences in size-to-charge ratio and detected by fluorescence (shown bottom 
right).26  
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Segmented Flow for Low Volume Sample Handling 
To improve throughput, samples could be introduced to microchips as segmented 
flow droplets. In such a method, aqueous samples (picoliter to microliter in volume) are 
encapsulated in an immiscible carrier phase, such as perfluorinated oil or air, allowing 
them to be easily manipulated without carryover.27 In the clinical laboratory, this method 
has been used since the late 1950s to automate sample analysis for clinical tests, such as 
urea and blood glucose.28, 29 Oil carrier phases have gained in popularity as they are much 
less compressible than air and analyte partitioning is minimized.30 Droplet formation can 
be achieved in several ways. For generating a large number of droplets from a single 
sample, flow focusing and tee-junctions can be used.31-34 To generate a few droplets of 
many samples, aspiration is used.35-38 Once formatted, a number of manipulations, akin to 
conventional bench-top chemistry, can be performed within droplets such as splitting,39-42 
fusion,43-47 mixing,48-52 sorting,53-56 reagent addition,38, 50, 52, 57, 58 and dilution59, 60 (Figure 
1-3). 
Droplet samples have the potential to drastically reduce sample consumption 
during HTS, which is doubly important because reagent cost and procurement are often a 
bottle neck during assay development and screening.61 By combining the above droplet 
transformations, such as reagent addition and rapid mixing, screening reactions can be 
prepared at the picoliter or nanoliter scale instead of the microliter scale. Starting with 
droplets generated from existing compound libraries, enzyme and substrate could be 
dispensed directly into droplets, and results could be read directly by fluorescence. Using 
this method, one group reported a 1000-fold reduction in assay time and a 1-million-fold 
reduction in cost compared to a conventional assay.53  
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Figure 1-3. Examples of manipulations and transformations possible with droplet 
samples. A) Asymmetric splitting of primary droplets into smaller secondary droplets by 
control channel geometry.42 B) Merging of two sequential droplets using a pillar array. 
The first droplet becomes stuck in the pillar array until merging with the second droplet. 
At this point, alternate flow paths for oil phase are blocked at the droplet is released.46 C) 
Rapid mixing is achieved within droplets through integration of turns into the 
microfluidic network. At each turn the orientation of the droplet changes leading to 
advective mixing.51 D) Fluorescence-activated droplet sorting (FADS) is achievable 
using external electrodes (shown in black and red at the top of the image). If a signal 
threshold is met, the electrode is energized causing droplets to deflect into the upper 
channel. Below the threshold, droplets automatically go into the lower channel (inset 
image).54 E) Reagent addition scheme using a hydrophilic side channel to reduce 
carryover.52 F) Serial dilution of droplets using a dilution chamber. Dilution droplets 
merge with the primary droplet (dark droplet centered in each frame) activating a fluidic 
valve and dispensing a tertiary droplet. Dilution of the primary droplet generates a serial 
dilution on chip.59 Figures reproduced with permission from individual publishers. 
Droplet strategies have been used in many novel applications related to high-
throughput analysis. In one of the first applications of droplet microfluidics, enzyme 
kinetics for ribonuclease A were measured with better than 1 ms resolution through on-
chip dilution and rapid mixing within droplets.60 Building on this work, screening of 
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protein crystallization conditions using less than 4 nL of solution per sample was 
reported.62 In a demonstration of HTS, high-resolution dose-response curves (10,000 
points per compound) for a library containing 704 compounds against protein tyrosine 
phosphatase 1B were analyzed in 4.2 hours (~450 Hz).63 Using more complex 
microfluidic platforms, drug cytotoxicity screening against encapsulated cells64, directed 
evolution of enzyme mutants53, generation of combinatorial reaction mixtures65, and 
bacterial susceptibility to antibiotics66 have been reported demonstrating that multiple 
steps and transformations of droplet samples are possible. 
The low sample requirements for CE and MCE (typically less than a few hundred 
picoliters) and the ability to manipulate droplets in a high-throughput manner make them 
a natural solution to sample introduction bottlenecks. Several groups have developed 
methods for coupling droplet-based samples to electrophoretic analysis. Due the fact that 
most carrier phases are non-conductive, droplet streams must be desegmented (i.e. the 
aqueous samples and carrier phase separated) prior to analysis by electrophoresis. This is 
typically achieved through either passive, which functions without intervention, or active 
methods that require external forces to achieve phase segregation. 
Passive droplet extraction is appealing because it requires no external input 
leading to simpler design and operation. These methods typically rely upon special 
channel geometries67-70 or differences in surface chemistry.71-76 Using a 
polydimethylsiloxane (PDMS) microfluidic device, one group developed a ‘comb’ 
structure that allowed selective removal of carrier phase from the droplet stream but 
prevent aqueous samples from passing due to high back pressure within the ‘comb’ 
(Figure 1-4A).70 They used this method to couple an LC separation to CE to achieve 2D 
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separations. The same group used an oleophilic film to wick away carrier phase prior to 
analysis of droplet contents by capillary gel electrophoresis71 or deposition for matrix 
assisted laser desorption ionization (MALDI)-MS (Figure 1-4B).73 Another group 
reported the use of octadecyltrichlorosilane chemistry to pattern selected channels 
hydrophobic, within a glass microfluidic device, to achieve selective extraction of the 
aqueous samples. This method was used to analyze droplet samples from a microdialysis 
in vivo chemical monitoring and enzyme assay samples (Figure 1-4C).75 
Active droplet extraction, while slightly more complex, affords opportunities to 
improve extraction robustness and selectivity.77, 78 Using an applied electric field, 
aqueous droplets were merged with a parallel aqueous stream while the oil carrier phase 
continued toward a waste outlet. This was applied to couple droplet samples to 
electrospray ionization (ESI)-MS by extracting samples into an MS friendly buffer 
immediately prior to spray (Figure 1-4D).77 
When coupled to electrophoretic analysis, the droplet sample is either wholly 
injected for analysis70, 71, 76 or a portion is injected. In the former method, the oil phase is 
typically removed immediately prior to injection of the droplet onto the electrophoresis 
channel. While this method is the simplest to implement, poor separation efficiency is 
common because droplet volume is typically much larger than an ideal MCE injection 
volume. Separation time is directly proportional to droplet spacing and high efficiency 
separations will require the use of very small droplets. To improve separation efficiency, 
injection of a portion of each droplet sample could be done. In one design, the extracted 
sample passes the separation channel inlet resulting in the injection of a small sample 
plug.72, 74 Therefore, injection volume is closely related to the sample flow rate and 
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droplet size. As with the previous method, separation time is directly proportional to 
droplet spacing. In another design, droplets were extracted before being sampled by EOF 
toward a voltage-gated injector. In effect, this is a dynamic sample reservoir allowing any 
combination of injection and separation parameters.75, 79 Indeed, this approach yielded the 
highest efficiency separations (223,000 plates) from droplet samples. None of these 
methods, however, were demonstrated to be compatible with HTS, which requires 
analysis of many distinct samples with minimal carryover. 
 
 
Figure 1-4. Examples of droplet desegmentation strategies for coupling to downstream 
analysis using either passive (examples in red box) or active strategies. A) Extraction of 
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droplets using special ‘comb’ channel geometry composed of thin PDMS pillars. Carrier 
oil is extracted through the pillars while the aqueous sample merges with the separation 
channel (top channel in each image).70 B) Schematic diagram of a device using oleophilic 
foam/film to remove carrier oil prior to droplets merging with the separation channel. 
This method was used for analysis of droplets by gel electrophoresis.71 C) Diagram of a 
glass device with modified surface chemistry for droplet extraction. The channel 
containing droplets is made hydrophobic through derivatization with 
octadecyltrichlorosilane while all other channels remain hydrophilic. Droplets are 
extracted across a thin ‘extraction bridge’ prior to analysis by MCE.79 D) Active droplet 
extraction utilizing applied electric fields for analysis of droplets by mass spectrometry. 
Droplets flow parallel to and are merged with an aqueous stream upon entering the 
external electric field. Carrier phase, which is non-conductive, continues on unaffected.77 
Reproduced with permission from individual publishers. 
One group has previously reported droplet-based sample introduction for high-
throughput screening by MCE. In their study, droplet samples were introduced into a 
glass microfluidic device through a hydrophobic patterned channel where they were 
extracted and analyzed by MCE. They demonstrated analysis of GTPase activity using a 
15 second separation (0.07 Hz) and throughput could be improved by simultaneous 
analysis of three samples within parallel electrophoresis channels.72 While a significant 
improvement on other methods and the first true demonstration of HTS by MCE, the low 
throughput and carryover (7 percent) associated with this implementation limit the 
methods potential. Additionally, the authors characterized enzyme activity but did not 
demonstrate screening a chemical library. 
Sirtuin Biology 
Sirtuins (SIRTs) represent an evolutionarily conserved class of nicotinamide 
adenine dinucleotide (NAD+)–dependent deacylases.80-83 SIRT mediated deacylation 
reactions consume NAD+ to generate a deacylated product, 2’-O-acetyl-ADP-ribose and 
nicotinamide. The sirtuin family is comprised of seven members located throughout the 
cell in areas such as the nucleus (SIRT1, SIRT2, SIRT6, and SIRT7), the cytoplasm 
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(SIRT1, and SIRT2), and the mitochondria (SIRT3, SIRT4, and SIRT5) (Figure 1-5).84 
Through modulation of lysine modifications on target proteins, sirtuins regulate many 
cellular functions, such as transcription, metabolism, and life span.85-87 Initially identified 
as NAD+-dependent deacetylases, only SIRT1 to SIRT3 have robust deacetylase activity 
while the deacetylase activity of SIRT4 to SIRT7 is reported as very weak or 
undetectable.84, 88, 89 However, recent research has revealed a number of novel lysine 
post-translational modifications – such as acyl,90, 91 succinyl,88, 92 glutaryl,93 malonyl,94, 95 
and crotonyl groups96, 97 – providing alternate targets for sirtuin activity.  
 
 
Figure 1-5. Primary cellular localization and function of sirtuins. SIRT1 and SIRT2 are 
present in the nuclear and cytosolic fractions.82 SIRT3, SIRT4, and SIRT5 are located in 
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the mitochondria. SIRT6 and SIRT7 are located in the nuclear fraction. For well-studied 
sirtuins, their targets and affected cellular processes are labeled and suppression (red 
lines) or activation (green arrows) is noted. A black line connecting a sirtuin to an acetyl 
group denotes a specific acetyl-lysine target. Reproduced with permission from Portland 
Press. 
One of the family members, SIRT5, readily catalyzes deacylation of negatively 
charged lysine modifications, such as malonyl, succinyl, and glutaryl moieties.88, 92-94, 98, 
99 Using x-ray crystallography, it was determined that the hydrophobic residues found in 
the substrate pocket of other sirtuins had been replaced by positively charged residues, 
such as arginine. This change may account for the unusual substrate preference of 
SIRT5.88 Although no striking biological phenotype has been reported for SIRT5 KO 
mice,100, 101 extensive hypersuccinylation and hypermalonylation is observed in SIRT5 
KO cell lines suggesting that SIRT5 may be the primary regulator of negatively charged 
lysine modifications within the cell.94, 98, 99 
Through removal of lysine modifications, SIRT5 regulates several metabolic 
enzymes (Figure 1-6).102 Carbamoyl phosphate synthase 1 (CPS1), which catalyzes the 
first step of the urea cycle, has increased activity when desuccinylated or deacetylated.100, 
103 3-hydroxy-3-methylglutaryl-CoA synthase 2 (HMGCS2), which is the rate-limiting 
enzyme in ketone body synthesis, is hypersuccinylated in the absence of SIRT5, and 
shows increased activity when desuccinylated by SIRT5.99 Through succinylation of 
pyruvate dehydrogenase complex (PDC) and succinate dehydrogenase (SDH), SIRT5 
suppresses cellular respiration.98 And, demalonylation of glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH) and aldolase B, SIRT5 regulates glycolosis and 
gluconeogenesis.95 
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Figure 1-6. Protein targets regulated by SIRT5 in vivo. Through removal of acetyl, 
succinyl, glutaryl, or malonyl groups from target lysines, SIRT5 activates (blue ellipse) 
or inhibits (green ellipse) target proteins. This affects downstream targets (yellow boxes) 
by increasing or decreasing target levels or activity (denoted by upward or downward 
facing arrows).102 Reproduced with permissions from Mary Ann Liebert, Inc. 
Due to regulation of metabolic pathways important to cancer progression, SIRT5 
may have an oncogenic role in specific cancers. SIRT5 activates superoxide dismutase 
(SOD1) in vivo, which plays a role in managing reactive oxygen species (ROS) within 
the cell.104 SOD1 overexpression or upregulation in lung105 and breast cancer,106 
respectively, may have a role in tumorogenesis. Because SIRT5 activates SOD1, these 
results suggest SIRT5 may be involved in tumor growth. In addition to these direct 
effects, SIRT5 is over-expressed in non-small cell lung cancer (NSCLC) and SIRT5 KD 
suppressed tumor formation in NSCLC.107 
  19 
These diverse functions demonstrate the need for pharmacological modulators of 
SIRT5 activity. Identification of SIRT5 modulators has been limited by a lack of known 
in vivo targets; however, recent identification of the above SIRT5 targets has increased 
efforts in this area. Adding to the complexity is the structural similarity between sirtuins. 
Many modulators are non-specific by targeting the conserved NAD+ binding pocket. To 
date, suramin has been most investigated as a SIRT5 inhibitor. Even though suramin 
possesses low micromolar potency against SIRT5,89 its activity against SIRT1 and SIRT2 
limits its efficacy in vivo. Several groups have reported synthetic peptide inhibitors with 
micromolar potency against SIRT5.108, 109 In light of the limited number SIRT5 
modulators identified to date, discovery of potent and specific modulators is necessary 
for basic biological and clinical applications.  
Within the field of sirtuin biology, much of the drug discovery has been focused 
on SIRT1 using optical detection methods, such as the commercially available Fluor-de-
Lys™ assay based around a two-step reaction (Figure 1-7).110-115 This assay utilizes a 
peptide-based substrate coupled to a 7-amino-4-methylcoumarin (AMC) tag via an amide 
bond adjacent to the terminal lysine. In the first step, SIRT1 catalyzed deacylation 
generates a substrate for trypsin. In the second step, trypsin releases the AMC tag through 
cleavage of the amide bond resulting in an increase in fluorescent signal equivalent to the 
sirtuin activity. These tend to be poor trypsin substrates and require high trypsin 
concentrations for efficient cleavage. In high-throughput settings, dispensing high 
viscosity solutions (i.e. concentrated trypsin solutions) can lead to large errors in sample 
preparation. However, the high assay sensitivity and availability of substrates for SIRT1, 
SIRT2, SIRT3, and SIRT5 make these assays desirable for many researchers. 
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Figure 1-7. Schematic of the commercially available Fluor-de-Lys™ assay for measuring 
sirtuin activity. In step 1, a sirtuin, or histone deacetylase, removes a lysine modification 
(i.e. acetyl group) from a peptide substrate conjugated to an AMC fluorophore generating 
a substrate for trypsin. In step 2, trypsin cleaves the amide bond linking AMC to the 
peptide releasing the fluorophore and generating and fluorescence signal.110 Reproduced 
with permission from Elsevier. 
In a well-known study, this assay was used to identify a number of potent SIRT1 
activators based around resveratrol, a polyphenol. These compounds increased SIRT1 
deacetylase activity 8-fold in vitro and improved yeast lifespan by 70 percent.112 
Although corroborated by in vivo studies in invertebrates, the SIRT1 activation could not 
be reproduced when using other peptide substrates.111, 116, 117 Further investigations 
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revealed that SIRT1 activation was caused by interactions between the bulky AMC tag 
and resveratrol that enhanced SIRT1 binding affinity. 
To avoid this ambiguity in screens for SIRT5 modulators, alternative SIRT5 
screening assays have been developed. Among the optical detection assays, monitoring 
nicotinamide depletion through coupled enzyme reactions is possible and is compatible 
with any peptide or protein substrate.111, 116-118 Using proteolytic cleavage by trypsin, 
assays based on fluorescence resonance energy transfer (FRET)119 or internally quenched 
substrates have been developed.120 However, these peptides require significant 
modification from natural substrate sequences, which could lead to artificial results 
during screening. Outside of optical assays, several assays utilizing LC-MS for analysis 
have been developed around natural peptides.88, 109, 121 
 
Dissertation Overview 
The research in this dissertation aims to continue development of electrophoresis-
based high-throughput screening to develop a novel droplet-MCE platform for routine 
HTS. It addresses the limitations of previous platforms by achieving low sample 
carryover, high efficiency separations, and moderate sample throughput into a reliable 
analysis platform. 
In Chapter 2, a novel PDMS-glass hybrid microfluidic device for analysis of 
droplet samples by MCE is developed. The design couples aspects of two previous group 
efforts into a design capable of robust droplet extraction with minimal carryover. To 
demonstrate the platforms utility for HTS, an electrophoretic mobility shift assay for 
protein kinase A (PKA) was developed around the known substrate Kemptide. A library 
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containing 140 test compounds was screened in 16 minutes using a 1 second MCE 
separation. This effort demonstrated a 2-fold improvement in sample throughput over 
previous MCE screening methods. 
In Chapter 3, electrophoresis-based HTS as developed in Chapter 2 was applied to 
a novel biological target – SIRT5. Due to its implication in metabolic pathways and 
potential impact on cancer biology, identification of SIRT5 inhibitors is vitally important. 
However, existing assays generally rely on fluorescence assays known to product false 
positive results. Therefore, we designed a novel SIRT5 substrate based on succinate 
dehydrogenase that allowed ultrafast MCE analysis. The assay robustness was 
demonstrated using a meso-scale screen against a library containing 1280 test compounds 
and 128 controls. The screen was completed within 46 minutes (0.5 samples per second) 
and generated over 11,000 electropherograms (8 MCE injections per sample) with an 
excellent assay Z-factor of 0.8. Several novel SIRT5 inhibitors were identified and 
potency was determined using dose-response analysis. This work demonstrated a 3-fold 
improvement in sample throughput over the design in Chapter 2. By optimizing 
separation conditions, separation time was reduced to 250 ms, while efficiency was 
increased 2-fold. Compared to previous CE-based sirtuin screens, throughput was 
improved 25-fold. 
Chapter 4 demonstrates the true potential of droplet-based samples for high-
throughput screening performing reaction and analysis within droplet samples. In 
previous methods, over 99 percent of sample volume was wasted, which leads to 
significant extra costs and time. A microfluidic reagent addition device was developed 
based on work done by previous members of our group and previously reported designs. 
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This design achieved a simple, easy to manufacture device cable of adding sub-nanoliter 
reagent volumes to nanoliter volume droplets. Carryover was less than 5 percent from 
sample to sample and the device was able to add reagents to over 9,000 droplets 
continuously. Reagents could be added to droplets at up to 10 Hz reliably allowing for 
rapid sample preparation. The utility for HTS was demonstrated with a screen of 1280 
compounds against SIRT5, which used 1,000-fold less reagent than the screen reported in 
Chapter 3. 
Chapter 5 discusses several future directions for droplet-MCE high-throughput 
analysis to more broadly apply this platform. These range from coupling droplet samples 
to alternative separation modes, such as gel electrophoresis and microchip 
electrochromatography, to development of a continuous droplet generation method. 
Additionally, preliminary work from alternate screening targets, such as protein-protein 
interactions, is reported. This method, which could rely on a peristaltic pump, would 
allow continuous generation and analysis of droplet samples by MCE, MS, or optical 
assays. 
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CHAPTER 2:  SUB-SECOND ELECTROPHORETIC SEPARATIONS FROM 
DROPLET SAMPLES FOR SCREENING OF ENZYME MODULATORS  
 
 
Reproduced with permission from (Guetschow, et al. Anal Chem 2014, 86, 10373-10379). 
Copyright 2014 American Chemical Society 
 
 
Introduction   
Modern high-throughput screening (HTS) technology allows for 104 to 105 
automated assays to be completed in one day. HTS has emerged as a powerful tool for 
many applications including drug, catalyst, and chemical probe discovery. The dominant 
form of HTS is based on assays performed in multi-well plates (MWP) with liquid 
handling and plate manipulation performed by robots and detection by optical plate 
readers. Although this approach has been successful, it has limitations. A fluorescent or 
other optical indicator must be coupled to or engineered into the biochemical reaction of 
interest. This requirement can increase development time, reagent costs, and potential for 
false signals wherein test compounds affect the indicator rather than the actual reaction. 
Further, in such schemes only one analyte is detected per reaction and interference from 
buffer components or test compounds is possible.  
Analysis of reaction mixtures by microchip electrophoresis (MCE) can avoid 
these limitations by separating substrates, products, and interfering species to eliminate 
the need of having a selective optical change upon reaction. Rapid separations are 
possible; however, reloading chips with fresh sample is a bottleneck for HTS. A 
commercial instrument overcomes these problems by “sipping” sample from wells and 
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pulling sample by vacuum into the separation channel.25 This powerful system allows 
continuous operation and a reliable interface to MWP; however, it does not reach the full 
potential of MCE because band broadening induced by flow through the separation 
channel gives reduced resolution requiring longer separation times. 
An alternative for screening many distinct samples by MCE is to deliver samples 
to the chip as droplets or segmented flow.72 In such a method, aqueous samples 
encapsulated in immiscible oil are pumped into the chip where the aqueous portion is 
extracted for injection onto the MCE channel. A significant advantage of this approach is 
that it is also compatible with the emerging trend of miniaturization by performing 
reactions at droplet scale (pL to nL volume) rather than MWP scale (1-30 µL). Droplet 
strategies have been used for several novel screens.38, 60, 62, 64, 122-124 
Although coupling droplets to MCE is an attractive prospect for HTS, most 
previous methods of interfacing have been developed for other applications (e.g., for two-
dimensional separations70, 125 or coupling to a sampling probe for chemical monitoring58, 
74, 126) and have limited proven utility for screening. Extraction of droplets has relied on 
modified surface chemistry,72, 74, 75 applied external fields,77 special channel 
geometries,67, 70 or the use of oleophilic films71, 73 to remove carrier oil. In these systems 
the extraction and injection processes are coupled so that compromises between droplet 
size, injection volume, and separation speed must be made. For example, an increase in 
droplet flowrate will reduce separation time and separation efficiency as the time between 
sample droplets decreases. Likewise, injection volume is directly correlated with droplet 
volume, which can lead to larger injections than are typical in MCE causing a reduction 
in separation efficiency. An exception was a method that allowed extraction followed by 
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electrokinetic gated injection.75 This approach to droplet-MCE interface yielded high 
efficiency (223,000 plates in 50 s separation); however, it was not shown to be 
compatible with screening, which requires analysis of many distinct samples and long-
term unattended operation of several hundred samples. Further, this method required a 
complex fabrication procedure involving surface chemistry patterning.  
Here we report a simplified approach to droplet-MCE interface. The method uses 
a minor modification of a standard MCE chip design. This method allows at least 700 
MCE injections from droplet samples and sub-second separations suitable for screening. 
We also demonstrate a method to track samples during a screen. The system was tested 
using a small scale screen of protein kinase A (PKA) modulators but in principle can be 
applied to any assays resulting in a change in analyte charge or size, such as peptide 
cleavage, dephosphorylation, and deacetylation. 
Materials and Methods 
Chemicals and Materials. All reagents were purchased from Sigma Aldrich (St. 
Louis, MO) with the following exceptions. 5-carboxyfluorescein (FAM)-labeled 
Kemptide was purchased from AnaSpec (Fremont, CA) and the catalytic subunit of 
cAMP-dependent protein kinase A was purchased from New England Biolabs (Ipswich, 
MA). The epigenetics compound library was purchased from Cayman Chemical (Ann 
Arbor, MI) and the kinase inhibitor library was obtained from the Center for Chemical 
Genomics at University of Michigan. 
PDMS Chip Fabrication. Polydimethylsiloxane (PDMS) tees were fabricated 
using a pour over method to align droplet tubing and microfluidic devices during 
operation. Briefly, a 360 µm o.d. capillary was taped in the bottom of a petri dish. A 100 
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o.d. capillary was glued into a 150 µm i.d x 360 o.d. sheath capillary such that ~3 mm of 
100 o.d. capillary was exposed. Two of these sheathed capillaries were taped on opposite 
sides of the 360 µm o.d. capillary with a 2-3 mm gap between them. PDMS was poured 
over the mold and cured at 75 °C for 15 min. After curing the mold was flipped and 
PDMS was poured on the other side and cured for an additional 20 min at 75 °C. After 
curing, all capillaries were removed and the device was cut to size using a razor blade.  
Glass Chip Fabrication. Glass chips were fabricated using photolithography and 
wet-etching by hydrofluoric acid (HF).127-129 Briefly, one slide is etched to 90 µm for the 
capillary insertion channel and to 50 µm for the sample channel. A second slide is etched 
to 90 µm for the capillary insertion channel and 5 µm for all separation channels. During 
etching of deep channels, other features were covered with HF resistant tape 
(Semiconductor Equipment Corporation, Moorpark, CA). After etching, access holes 
were drilled with a 500 µm drill bit (Kyocera Tycom, Costa Mesa, CA). Glass slides 
were washed for 20 min in piranha solution (sulfuric acid:hydrogen peroxide, 4:1) and for 
40 min in heated RCA solution (ammonium hydroxide:hydrogen peroxide:water, 1:1:5). 
Slides were rinsed with water, aligned under a microscope, and annealed at 610 °C for 8 
h. Reservoirs and access ports (IDEX Heath and Science, Oak Harbor, WA) were 
attached at the access holes and a 40 µm i.d. x 150 µm o.d. x 2.5 mm long extraction 
capillary was waxed in place in the capillary insertion channel. (See Appendix A for 
additional modifications to glass microfabrication necessary to avoid pinholes and 
anisotropic etching.)  
Microfluidic Chip Operation. All reservoirs and channels on the glass chip were 
primed with separation buffer (10 mM sodium tetraborate, pH 10, 0.9 mM 
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hydroxypropyl-β-cyclodextran) to remove air bubbles. Voltage for electrophoresis was 
applied using a CZE1000R power supply (Spellman, Hauppague, NY) and a high-voltage 
relay (Kilovac, Santa Barbara, CA) was used to control electrokinetic-gated injection.130, 
131 Detection was accomplished using an in-house confocal laser induced fluorescence 
(LIF) detector. Briefly, the 488 nm line from a solid-state laser (CrystaLaser, Reno, NV) 
was directed through a 488 ± 10 nm band pass filter and a 10X objective lens. Emission 
was filtered through a 520 ± 10 nm band pass filter and detected by a photomultiplier 
tube (R1477, Hamamatsu, Bridgewater, NJ). Current from the PMT was amplified by a 
current preamplifier (Stanford Research Systems, Sunnyvale, CA) and monitored using 
an in-house LabVIEW program (National Instruments, Austin, TX). Data analysis was 
done using Cutter 7.0,132 Excel 2011 (Microsoft, Redmond, WA), and Igor Pro 6.32 
(Wavemetrics, Inc., Lake Oswego, OR). 
Droplet Generation from MWP. Droplets, segmented by perfluorinated oil 
(100:1, perfluorodecalin (PFD): perfluorooctanol (PFO)), were generated from a 
multiwell plate using a method previously described. Droplet samples were pulled into a 
150 µm i.d. x 360 µm o.d. HPFA tube (IDEX Health and Science, Oak Harbor, WA) 
using a syringe connected to a PHD 200 syringe pump (Harvard Apparatus, Holliston 
TX) operating in refilling mode. After priming the syringe and tubing with 100:1 
PFD:PFO, droplets were generated using a computer-controlled XYZ-positioner to move 
the tubing from well to well in a defined pattern. Samples were covered with carrier oil to 
prevent sample evaporation and aspiration of air into tubing.37, 38 
Protein Kinase A Modulator Screen and Droplet Analysis. Each sample in the 
screen was prepared in 20 µL with final concentrations of 50 mM Tris, pH 7.5; 10 mM 
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MgCl2; 200 µM ATP; 15 µM FAM-Kemptide; and, 3.75 nM protein kinase A. During 
screening experiments, test compounds from the kinase inhibitor library were deposited 
using a Caliper Sciclone (PerkinElmer, Waltham, MA) into a 384-well plate (0.1 to 12.5 
µM final concentration). For the epigenetics compound library, compounds were pipetted 
manually into a 384-well plate (5 µM final concentration). Control samples contained 
dimethyl sulfoxide (DMSO) at equal volume to test compounds. Negative controls 
contained no inhibitor (mimicking no inhibition), and positive controls contained no 
enzyme (mimicking 100 percent inhibition). Reactions were incubated at room 
temperature for 30 min and quenched with 80 µL of 15 mM ethylenediaminetetraacetic 
acid (EDTA) and placed on ice. Immediately prior to droplet generation, 90 µL of each 
sample was transferred to a modified 384-well plate designed to allow samples to be 
covered by carrier oil. To extract droplets, a 50 µL syringe filled with water was attached 
to a 40 µm i.d. x 150 µm o.d. capillary and connected to the PDMS tee after the 
extraction region and the PDMS chip was primed with water. Next, tubing containing 
sample droplets was inserted until flush with the extraction capillary in the glass chip and 
connected to a 100 µL syringe on a syringe pump. Droplets were pumped into the PDMS 
chip at 360 nL/min and injections were made every 1 s. 
Results and Discussion 
Droplet extraction from segmented flow. Our strategy for high throughput 
electrophoresis is to introduce a series of samples to the microchip as segmented flow. A 
primary challenge of achieving rapid MCE analysis from segmented flow is separation of 
the oil phase from sample prior to MCE analysis. To simplify the process of droplet 
extraction, we used the native properties of glass (hydrophilic) and PDMS (hydrophobic) 
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to extract droplets through a hybrid device (Figure 2-1). An advantage of this approach is 
that we take advantage of the native surface chemistry of these materials to achieve 
extraction, this eliminating the need for surface patterning. A hybrid device has the added 
benefit of decoupling the extraction and analysis stages for better performance. Also, it 
has the practical advantage that a new extraction or analysis chip can be substituted if it 
stops working without the need to fabricate a new device. 
 
Figure 2-1. Schematic of PDMS-glass hybrid microfluidic device for analysis of 
segmented flow samples. Aqueous droplets (blue colored) are extracted by the extraction 
capillary and sampled by EOF in the sampling channel towards the injection cross. 
During injection, the positive high-voltage power supply is floated to allow injection of a 
discrete sample plug into the separation channel. The positive high-voltage is applied 
again during separation and excess sample is gated to the waste channel. To assist 
extraction waste droplets (green colored) are generated after the extraction point to 
provide a slight backpressure for extraction. 
 In this device, a length of Teflon tubing containing sample droplets is positioned 
orthogonal to the inlet of a fused silica extraction capillary that is interfaced to the glass 
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MCE chip using a tee molded from PDMS (Figure 2-1). The fused silica extraction 
capillary also acts as a conduit to the glass MCE chip. As droplets exit the Teflon tubing, 
aqueous samples are extracted into the hydrophilic fused silica extraction capillary while 
the oil phase continues towards the outlet of the hydrophobic PDMS device. The 
extracted sample droplet fills the extraction capillary and sampling channel (Figure 2-1) 
where it can be injected onto the MCE channel using an electrokinetic flow gate.130, 131 
Subsequent samples wash the extraction capillary and sampling channel out for serial 
injections.  
Although the inherent surface chemistry of the extraction capillary and PDMS tee 
will favor droplet extraction and oil phase flow past the extraction point, it is also 
necessary to use proper capillary and channel dimensions so that capillary force and back 
pressure are balanced to favor droplet but not oil flow into the extraction capillary. In 
other words, with high flow rates, wide bore extraction capillaries or narrow PDMS 
channels, oil can be forced into the extraction capillary. In the opposite case, aqueous 
samples will not be fully extracted. For the flow rates and chip dimensions used here, a 
40 µm i.d. fused silica capillary generated good extraction (i.e., the entire aqueous 
droplet) with no oil phase entering the extraction capillary. We visually observed that 
droplet extraction was more reliable by elevating pressure slightly at the outlet of the 
PDMS tee. This pressure was created by a pumping water at 150 nL/min into an inlet 
positioned downstream of the extraction point (Figure 2-1, waste droplet generator).  
The chip was also designed to minimize carryover between samples. To reduce 
carryover, dead volume from the extraction point on the PDMS device to the sampling 
point, on the glass device was minimized through the use of narrow bore capillaries and 
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short capillary lengths (3.3 nL). With this small volume, we anticipated that ~10 nL of 
sample would be needed to washout the capillary and prevent carryover. 
To evaluate the extraction efficiency and sample carryover in the extraction 
channel, we monitored fluorescence as alternating pairs of 8 nL droplets containing 
fluorescein at high (6 µM) and low (2 µM) concentration were pumped through the 
system. Droplets are detected as square-topped pulses within the Teflon tube (Figure 2-2) 
reflecting signal from fluorescence within the droplet and no signal for the oil. After 
extraction the droplets fill the extraction capillary and become continuous phase without 
pulses between droplets of the same concentration (red trace, Figure 2-2A). In the 
transition from high to low concentration, the signal decreases and then stabilizes. The 
timing of the transition suggests that the sample is 80% washed out by the first droplet 
and 98% washed out by the time the second droplet is extracted. In the transition from 
low to high concentration, the signal stabilizes more quickly. These results show that 
carryover should be minimized using 2 droplets. The exact volumes required may depend 
on the sample type being used, e.g. if surface adsorption is greater more rinses may be 
required.  
If the back pressure was not provided by the extra flow the transitions were longer 
and not as reliable as shown by the increase in carryover in the red trace in Figure 2-2B 
starting after 60 s. This result coincides with incomplete extractions and sample buildup 
at the capillary inlet. By using the waste droplet to increase pressure in the extraction 
zone, sampling buildup was greatly reduced and carryover between samples was less than 
2% (Figure 2-2A). At least 500 droplets, the most tested, could be extracted reliably with 
this approach.  
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Figure 2-2. Comparison of extraction of droplet stream without (A) and with (B) waste 
channel droplets shows the effect of added backpressure on extraction efficiency. When 
waste droplets are present intensity of droplets before extraction (black trace) is nearly 
identical to intensity of sample after extraction (red trace) and transitions from high to 
low intensity occur rapidly suggesting that each droplet rapidly rinses out the previously 
extracted droplet from the glass chip. Without waste droplets, sample intensity is not 
stable over time on the MCE chip as sample droplets mix. Detection point for droplets 
before extraction (black star) and after extraction (red star) are marked on the schematic 
in Figure 1. 
 MCE injection from droplets. After extraction, aqueous samples fill the sample 
channel, which acts as the sample reservoir in a cross-style injector in MCE.130, 131 In this 
way, the hybrid chip acts as a means to rapidly introduce new samples to a microfluidic 
device while maintaining injection geometry known to have high performance.75, 130, 131, 
133 To make an injection, sample is directed towards the injection cross by electroosmotic 
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flow (EOF) using applied electric fields. During separation, this sample stream is gated 
towards a waste reservoir on chip by a cross flow, which also provides fresh separation 
buffer to the electrophoresis channel. During injection, the gating flow is shut off by a 
high-voltage relay to allow a small plug of sample to be injected into the separation 
channel for analysis. Importantly, unlike many other designs used for droplet MCE, the 
volume and shape of the plug that is injected is controlled independently of the extraction 
process enabling higher efficiency for a given separation time. 
Using this injection method, screening reaction samples containing substrate, 
product, and rhodamine were separated with good efficiency. For example, using a 10 
mM sodium tetraborate buffer at pH 10 and an electric field of 2000 V/cm, separation 
efficiency of 16,000 plates for a 1 s separation in 0.5 cm was routinely achieved. By 
making a discrete injection from a larger sample droplet, injection volume is not 
controlled by droplet volume and multiple injections can be made from each sample 
droplet. Further, the separation time is not limited by droplet spacing, as is the case when 
an injection is made from each droplet72, 74 or whole droplet injection is used.70 We found 
that these differences were useful for HTS. Using a gated-injection scheme, coupling 
MCE to 2D separations or other sampling probes for chemical sensing by segmented 
flow should also be possible.  
 Mobility shift assay of enzymatic reactions. Phosphorylation of kemptide by 
PKA was used as a test assay for this system (Figure 2-3A). Injection of the reaction 
mixture results in two peaks in the electropherogram due to the unphosphorylated 
substrate and phosphorylated product, which migrates slower due to the addition of a 
negative charge through the phosphate group (Figure 2-3B). By injecting substrate alone, 
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only the first peak is present and both substrate and product migration times were 
verified. 
 
 
Figure 2-3. Protein kinase A catalyzed phosphorylation of kemptide (A) and resulting 
electropherogram (B) for the separation of the reaction mixture. Product and substrate 
were separated in 0.5 cm using an applied field of 2000 V/cm and a 30 ms injection. 
Due to the large number of samples generated in HTS a rapid MCE separation is 
required. The change in charge on kemptide due to phosphorylation allowed for easy 
separation of the substrate and product peak. A separation in < 1 s was achieved using a 
high electric field (2000 V/cm) and a short separation length (0.5 cm) without sacrificing 
separation resolution. This separation was fast enough to allow at least three injections 
per droplet that entered the capillary (Figure 2-4A). Indeed, the effect of droplet clearing 
can be observed in the relative peak heights for each electropherogram. The first three 
injections shown in the trace in Figure 2-4 correspond to the second droplet for a sample 
and the peak heights are stable. The next four traces correspond to a new sample that has 
been extracted. Fluctuation in peak height for rhodamine, substrate, and product is 
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observed as the droplet washes out the reservoir and reaches a stable signal, similar to the 
continuous measurements depicted in Figure 2-2A. The last three traces correspond to the 
second droplet being extracted and entering the sample reservoir. By this time, the peak 
heights have once again stabilized for all traces. Thus, these results illustrate that use of 
two droplets per sample, the first to rinse the small reservoir and the second to provide a 
stable signal, allows for analysis of discrete samples in series. In principle, the number of 
injections per droplet can be varied by using different size droplets and flow rates. 
Likewise, the amount of rinse required could be decreased by using even lower dead 
volumes. Obtaining multiple injections per droplet can be valuable in achieving reliable 
results at the expense of throughput.  
At this high of a separation speed, reproducibility was still good. For example, we 
performed over 700 injections in ~12 min with a migration time RSD of ~2%.  Reaction 
yield, calculated as P/(P+S), where P and S are the product and substrate peak area 
respectively, had an RSD of 7% (n = 8) for negative control samples spread throughput 
the sample set. For a series of injections from a single sample, the RSD was generally 
less than 5% (n=3). As observed in the substrate peak area trace in Figure 2-4B, droplet 
extraction causes a slight increase in pressure on the glass device leading to an increase in 
substrate peak area for that injection. Using reaction yield, instead of raw peak area, for 
analysis combined with averaging three injections per sample mitigates this effect. 
 Indexing droplet data using a fluorescent dye. When analyzing a series of 
samples reformatted from a MWP to droplet streams it can be difficult to determine 
which electropherograms belong to each sample. This is especially true for the passive 
extraction/injection system used here. Thus, even though droplets are introduced to the 
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chip at a constant flow rate and injections are performed at a constant rate; we found that 
the exact number of injections per sample (formatted as 2 droplets of 8 nL each) can vary 
from 6 to 8. We attribute this primarily to slight variations in sample size, sample flow 
rate, and the timing of injection relative to the droplet extraction. The variability in 
injection number per droplet means that it is necessary to mark each droplet to register an 
electropherogram with test analyte or sample. Figure 2-4B illustrates the peak area for a 
series of electropherograms from assay samples. With the exception of a positive control, 
which has a low product peak area, determining which data corresponds to each sample is 
nearly impossible. To avoid this problem a marker compound, rhodamine 110, was added 
to every other sample to provide data indexing. During data analysis, every other sample 
(corresponding to a train of approximately 6 injections) will have a rhodamine peak in the 
electropherogram as can be observed in Figure 2-4A. Using changes in rhodamine 
intensity as a guide, the start and end point for each sample can be quickly identified 
across all electropherograms (black trace, Figure 2-4B). For example, from 20-100 
seconds 10 samples, each containing a different test compound, are analyzed, but 
substrate and product peak areas remain stable because none of the compounds inhibit 
PKA. However, utilizing the changes in rhodamine peak area, the data can be 
deconvoluted to reveal each individual sample. 
Droplet-based screen of protein kinase A modulators. To test our novel 
droplet-MCE method, we screened two small molecule libraries against PKA for 
inhibitory activity. The kinase inhibitor library contained 60 test compounds with known 
activity at various kinases and the epigenetics library contained 80 test compounds that 
are known to act at proteins involved in histone modification and not necessarily kinases. 
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A total of 168 samples were analyzed for the primary screen including positive and 
negative controls. Samples were prepared and reacted as outlined in the experimental 
section and two droplets were generated for each sample. Samples were analyzed in 
batches of 96 for a total of ~200 droplets per analysis. Analysis of each batch required 
approximately 12 min. By generating the next set of samples during analysis, near 
continuous analysis by MCE is possible achieving sample throughput of 0.16 samples/s. 
 
 
Figure 2-4. Electropherograms and raw peak area data demonstrating sample clearing 
and indexing for screening by MCE. (A) Electropherograms showing injection and 
separation of rhodamine (R), substrate (S), and product (P) and transition from a sample 
without rhodamine to a sample with rhodamine demonstrating complete sample clearing 
by two droplets. (B) Extracted peak areas for rhodamine (black trace), substrate (red 
trace), and product (blue trace) for analysis of 12 samples – two controls and ten test 
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compounds. Changes in rhodamine peak height were used to determine start and end 
points for each compound to calculate reaction yield. 
Reaction yields were calculated for each sample and normalized to the average 
positive control reaction yield (Figure 2-5). An inhibition threshold was set at 80%, 
which corresponds to three standard deviations below the normalized positive control 
yield across all experiments (n = 40). Any compounds with reaction yields below this 
threshold were identified as inhibitors of PKA with lower reaction yields denoting 
stronger inhibitors. In total, 25 test compounds (7 from the epigentics library and 18 from 
the kinase library) were identified as potential hits during the primary screen and all of 
these compounds showed a dose-dependent inhibition of protein kinase A during follow 
up screening experiments. Two false negatives were identified during the screen. One 
compound, H-89 – showed no inhibition at 12.5 µM, but was active at three lower 
concentrations. The second compound, piceattanol, was present in both compound 
libraries but was only active in the kinase library. However, a dose-dependent response 
was observed suggesting this is a true hit compound and was likely degraded in the 
epignetics compound library. Overall the assays had a high Z’-factor of 0.8 making 
identification of both strong and weak inhibitors possible. 
Follow up dose-response curves for H-89 and ellagic acid (Figure 2-6), two 
known protein kinase A inhibitors, showed good agreement with accepted IC50 values. 
For H-89, the experimental IC50 value was 89 ± 1 nM and the IC50 value for ellagic acid 
was 1.00 ± 0.01 µM. Previous results using filter based assays with [γ-32P]ATP were 135 
nM for H-89,134 and 3.5 µM for ellagic.135 
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Figure 2-5. Screening 140 small molecules against protein kinase A reveals 25 hit 
compounds based on the inhibitor threshold (red line). All reaction yields are normalized 
to the average negative control yield (blue line). With the exception of compound 25, 
which is plotted at 2.5 µM, compounds 1-60 were tested at 12.5 µM and compounds 61-
140 were tested at 5 µM. 
Comparison to Other Systems. It is interesting to consider the potential of this 
system relative to the commercial MCE screening system described in the introduction. 
Using a comparable peptide substrate and product, the Caliper instrument was able to 
analyze samples from multiwell plates using a 42 s separation in a single channel 
corresponding to 0.02 samples/s.25 In a previous report, we used a droplet extraction 
method to achieve 0.07 samples/s for 1-channel. The efficiency was much lower because 
the droplet volume and flow rate determined the injection volume. In a previous report, 
the same extraction geometry achieved an average separation efficiency of 53,500 plates 
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for a 12 s separation of three amino acid neurotransmitters.74 The droplet MCE system 
achieves about ten-fold higher rates per channel even though replicate injections are 
performed and some replicates are wasted on carryover. This increase in throughput is 
due to the higher efficiency enabled by combination of droplet introduction and 
electrokinetic injection. A further potential advantage of droplet-based sample 
introduction is a substantial reduction in reagent consumption by utilizing an all-droplet 
format, i.e. reactions performed in droplets,38, 63 which could achieve over a 1000-fold 
reduction in reagents. While these observations demonstrate a significant potential 
advantage of the droplet MCE approach, further testing and development is required 
before a droplet system could compete in terms of robustness and routine use for 
screening 104 to 105 samples and continuous operation.  
 
 
Figure 2-6. Dose-response curves for H-89 (black trace) and ellagic acid (red trace) 
generated from protein kinase A screening data. The measured IC50 values agree with 
literature values of 150 nM134 and 3 µM135 for H-89 and ellagic acid, respectively. 
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Conclusion 
 This work has demonstrated a novel droplet extraction method for coupling 
segmented flow to MCE that uses the native properties of PDMS and glass to separate the 
two phases in segmented flow. We demonstrated the utility of this sample introduction 
method combined with MCE for HTS by performing a proof-of-concept screen with PKA 
and a set 140 small molecules. Each sample consisted of two droplets and approximately 
6 injections were made per sample. This equates to an injection throughput of 1 Hz and a 
sample throughput of 0.16 Hz, which would allow for analysis of  >10,000 samples per 
day. In order to increase sample throughput without sacrificing separation resolution or 
data quality, parallel analysis would be required and could be achieved by fabricated 
multiple separation channels per device. Additionally, this platform is applicable to other 
screening assays and other droplet-MCE applications, such as coupling stages of a 2D 
separation or chemical sensing from sampling probes. 
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CHAPTER 3:  IDENTIFICATION OF SIRTUIN 5 INHIBITORS BY 
ULTRAFAST MICROCHIP ELECTROPHORESIS USING NANOLITER 
VOLUME SAMPLES 
Reproduced with permission from (Guetschow, et al. Anal Bioanal Chem 2015, DOI: 10.1007/s00216-015-9206-0). 
Copyright 2015 Springer 
 
Introduction 
 Sirtuins are an evolutionarily conserved class of nicotinamide adenine 
dinucleotide (NAD+)–dependent deacylases comprised of seven members (SIRT1-
SIRT7).80, 81 The SIRT mediated deacylase reaction consumes NAD+ generating a 
deacylated product, 2’-O-acetyl-ADP-ribose, and nicotinamide. Recent research has 
revealed novel catalytic functions for sirtuins, such as deacylation,90, 91 desuccinylation,88, 
92, 94 deglutarylation,93 demalonylation,94, 95 and decrotonylation96, 97, with SIRT5 
preferentially targeting succinyl, glutaryl, and malonyl moieties.88, 92-95, 98, 99 Through 
removal of these modifications, SIRT5 regulates the activity of many metabolic enzymes, 
such as carbamoyl phosphate synthetase 1 (CPS1),100, 103 superoxide dismutase 1 
(SOD1),104 succinate dehydrogenase (SDH),98 pyruvate dehydrogenase complex (PDC),98 
and 3-hydroxyl-3-methylglutaryl-CoA synthase 2 (HMGCS2).99 SIRT5 regulates 
glycolysis through demalonylation of glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) and aldolase B, among other targets.95 SIRT5 knockout cells show extensive 
hypersuccinylation. Although no striking biological phenotype or abnormality is 
observed for SIRT5 knockout cell lines,101 SIRT5 may play a role in cancer biology102, 136 
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as suggested by its overexpression and reported pro-proliferative role in lung cancer.104, 
107 
 Because of the diverse roles that SIRT5 plays within cells, identification of small 
molecule modulators of SIRT5 activity could have biological and clinical applications. 
Development of robust HTS assays for SIRT5 is necessary to enable rapid testing and 
identification of modulators. To date, much work has been done screening other members 
of the sirtuin family through optical assays, such as the commercially available Fluor-de-
Lys™ assay based on 7-amino-4-methylcoumarin (AMC).111-115 After catalytic removal 
of the lysine modification by a sirtuin, the AMC probe is accessible to cleavage by 
trypsin leading to an increase in fluorescent signal.110 This type of assay was used for the 
identification of Sirtuin 1 activators reported to increase lifespan in invertebrates.112 
While these assays are amenable to HTS, the close proximity of dye molecule and lysine 
residue has resulted in artifactual results during screening.111, 116, 117 To avoid these 
limitations, groups have developed alternative assays for SIRT5 screening based on 
optical detection of nicotinamide formation,118 inclusion of fluorophore-quencher pairs in 
the substrate,120 high-performance liquid chromatrography-mass spectrometry (HPLC-
MS),88, 109, 121 and fluorescence-resonance energy transfer.119 However, the number of 
compounds screened has been limited and the throughput required for large-scale 
screening has not been demonstrated. 
 Previously, electrophoresis assays have been used for screening of sirtuins,23-25, 
137-139 GTPase,72 and other enzymes.140, 141 Although these assays typically use 
fluorescent substrates, the label is often located remote from the target residue reducing 
the likelihood of false positives due to non-specific interactions. Conventional capillary 
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(CE) or microchip electrophoresis (MCE) methods use auto-samplers or manual sample 
loading leading to a maximum throughput of a few samples per minute.  
Droplet-based sample introduction for CE and MCE has recently been 
demonstrated for screening72, 142 and other assays70, 71, 74-76 as a way to improve sample 
introduction to microfluidic devices. Indeed, we previously developed a droplet-MCE 
assay for protein kinase A (PKA) capable of analyzing 8 samples per minute.142 Due to 
the small number of compounds tested in these screens, the method robustness required 
for routine high-throughput analysis has not been demonstrated. Herein we report the use 
of droplet-MCE with 3-fold improved throughput over prior studies for a screen of 1280 
compounds against SIRT5.  
Materials and Methods 
 Chemicals and Materials. Unless otherwise specified all reagents were 
purchased from Sigma Aldrich (St. Louis, MO). SDHA-derived peptide was synthesized 
by GenicBio Limited (Shanghai, China). All test compounds were from the Prestwick 
Chemical Library (Prestwick Chemical, Washington DC) and were supplied by the 
Center for Chemical Genomics at the University of Michigan or from the Epigenetics 
Screening Library (Cayman Chemical, Ann Arbor, MI). 
 Microfluidic Device Fabrication. Polydimethylsiloxane (PDMS) droplet 
extraction devices were prepared using a pour over method as previous described.142 
Glass microfluidic devices were fabricated using photolithography and wet chemical 
etching by hydrofluoric acid.127-129 Each device is fabricated from two etched pieces of 
glass that are aligned prior to bonding. One slide was etched to 80 µm for the capillary 
insertion channel and sample channel. The second slide was etched to 80 µm for capillary 
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insertion and 3 µm for separation channels. During etching of deep channels, other 
features were covered with HF resistant tape (Semiconductor Equipment Corporation, 
Moorpark, CA). After etching, fluidic access holes were made with a 0.5 mm drill bit 
(Kyocera Tycom, Costa Mesa, CA). Glass slides were washed for 20 min in piranha 
solution (sulfuric acid:hydrogen peroxide, 4:1) and for 40 min in heated RCA solution 
(ammonium hydroxide:hydrogen peroxide:water, 1:1:5). Slides were rinsed with water, 
channels were aligned under a microscope, and bonded at 610 °C for 8 h. Reservoirs 
(IDEX Health and Science, Oak Harbor, WA) were attached at the access holes using 
epoxy and a 30 µm i.d. x 150 µm o.d. x 1 mm long extraction capillary was waxed in 
place in the capillary insertion channel. 
 Droplet Generation from Multiwell Plate. Droplet formation followed the 
procedure previously published.35 Droplets segmented by perfluorodecalin (PFD) were 
generated from modified polypropylene 384-well plates (Nunc ShallowWell, Thermo 
Scientific, Waltham, MA) and collected into 150 µm i.d. x 360 µm o.d. HPFA+ tubing 
(IDEX Health and Science, Oak Harbor, WA). Well height across the entire plate was 
reduced by 1.5 mm using a CNC milling machine allowing samples to be covered by 
carrier oil to prevent evaporation and aspiration of air bubbles. For droplet formation, 
multiwell plate (MWP) and tubing were mounted onto a computer controlled XYZ-
positioner so that the tubing inlet could move freely above the wells. The tubing outlet 
was connected to a 100 µL syringe mounted in a PHD 200 syringe pump (Harvard 
Apparatus, Holliston, TX) and both were primed with PFD to remove any air bubbles.37 
With the syringe pump operating in refilling mode (1000 nL/min), the tubing inlet was 
moved from well to well in programmed pattern to generate droplets at 0.75 droplets per 
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second. Briefly, the computer was programmed to move at 2000 mm/s, which was the 
maximum rate of linear motion. For each sample droplet, the tubing would dwell in the 
aqueous phase (420 ms) and in the oil layer (150 ms). Addition oil phase would be 
aspirated as the tubing moved from well to well. The final droplet volume was 8.2 ± 0.3 
nL and each oil spacer was 10.0 ± 0.4 nL. After formation of droplets a short oil plug 
(~10 mm) is aspirated into the tube to prevent sample loss caused by flow induce when 
making connections. 
 Microchip Electrophoresis Analysis with Droplet Samples. Prior to each 
experiment, all fluidic channels were filled with separation buffer (10 mM sodium 
tetraborate, pH 10) ensuring no air bubbles remained. Positive (+2 kV) and negative (-3 
kV) high voltage (CZE1000R, Spellman, Hauppague, NY) was applied to the 
microfluidic device via platinum electrodes at the fluid reservoirs. Sample was 
electrokinetically injected130, 131 for 15 ms using a high-voltage relay (Kilovac, Santa 
Barbara, CA) controlled by an in-house LabVIEW program (National Instruments, 
Austin, TX). Detection was accomplished using a confocal laser-induced fluorescence 
detector. Briefly, a 488 nm line from a solid state laser (CrystaLaser, Reno, NV) was 
directed through a 488 ± 10 nm band pass filter and reflected by a 500 nm dichroic mirror 
into a 40X objective lens. Emitted light was collected by the same objective and passed 
through the dichroic mirror. The emitted light filtered through a 520 ± 10 nm band pass 
filter and 400 µm pinhole prior to being detected by a photomultiplier tube (R1477, 
Hamamatsu, Bridgewater, NJ). Current from the PMT was amplified (SR570 current 
preamplifier, Stanford Research Systems, Sunnyvale, CA) and monitored using in-house 
LabVIEW control software. Data were sampled at 1000 Hz using a 16-bit data 
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acquisition card (PCI-6036E, National Instruments Corp., Austin, TX). 
Electropherograms were analyzed with Cutter 7.0 132. Statistical analysis and plotting was 
done in Excel 2011 (Microsoft, Redmond, WA), and Igor Pro 6.32 (Wavemetrics, Inc., 
Lake Oswego, OR). 
 Droplet samples were introduced as outlined previously. A length of tubing 
containing sample droplets connected to a 100 µL syringe via a union and the outlet was 
inserted in to the PDMS extraction device at a 90° angle to the extraction capillary inlet. 
Downstream of the extraction region, a 40 µm i.d. x 150 µm o.d. fused silica capillary 
connected to a 100 µL syringe is inserted into the device to generate waste droplets that 
promote extraction by increasing backpressure at the extraction point. Droplets were 
pumped into the extraction device at 700 nL/min and electrokinetic injections were made 
at 4 Hz. 
 In Vitro PDC Desuccinylation Assay. Porcine heart PDC (Sigma Aldrich, St. 
Louis, MO) was purified by centrifugation at 135,000xg for 2 hours in 100 mM 
potassium phosphate, pH 7.5, 0.05% lauryl maltoside, 2.5 mM EDTA, and 30% glycerol. 
Desuccinylation reactions were carried out on 30 μg of purified porcine heart PDC in a 
final reaction volume of 60 μl in presence of 25 mM Tris-Cl, pH 8.0, 200 mM NaCl, 5 
mM KCl, 1 mM MgCl2, 0.1% PEG 8000, and 3.125 mM NAD+ at 37°C for 2 hours. 
Where indicated, 10 μg of SIRT5 or SIRT5H158Y (expressed and purified in house) was 
added. During incubation, tubes were occasionally agitated. Following desuccinylation, 
15 μl each reaction was analyzed by immunoblotting with a succinyl-lysine antibody 
(PTM Biolabs, Inc, Chicago, IL). After analysis, the membrane was stripped and re-
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probed for PDHA1 (Abcam, Cambridge, MA) and SIRT5 (Cell Signaling Technology, 
Danvers, MA). 
 Peptide-based SIRT5 Assay. Assay conditions were developed using a novel 
succinyl-lysine peptide derived from succinate dehydrogenase.98 The substrate peptide 
(GGQSLK[succ]FGKG) was labeled at the N-terminus with 5-carboxyfluorescein (5-
FAM) and yielded a desuccinylated peptide (GGQSLKFGKG) as a product. Reactions 
were performed in 10 mM Tris, pH 8 containing 1 mM dithiothreitol (DTT) with enzyme 
concentration fixed at 10 nM. Reactions were stopped by dilution with 1.5 volumes of 10 
mM sodium tetraborate, pH 10. Kinetic parameters were determined using substrate 
concentrations ranging from 0 to 50 µM at time points from 0 to 30 minutes. Kinetics 
data was fitted using the Michaelis-Menton model in GraphPad Prism 6. Assay 
conditions were validated using a small-scale screen of the Epigenetics Screening 
Library. 
 High-throughput SIRT5 Screening. All screens were performed at 10 µL final 
volume in a modified low volume MWP and were prepared using a MultiDrop Combi 
(Thermo Scientific, Waltham, MA). A Caliper Life Science Sciclone ALH300 
(PerkinElmer, Waltham, MA) was used to deposit 50 nL of 2 mM test compounds into 
MWPs containing 5 µL of 2X reaction buffer (20 mM Tris, pH 8, 2 mM DTT). To index 
samples during analysis, 1 µL of 1 µM rhodamine 110 was added to even number 
columns and 1 µL of water was added to odd number columns. Next, 1 µL of 10 µM 
peptide was added to all wells and 3 µL of 33 nM SIRT5 was added to initiate reactions. 
Final reaction conditions were 1 µM peptide, 10 nM SIRT5, and 10 µM test compound 
with 0.5% DMSO. Reactions were quenched by addition of 15 µL of 10 mM sodium 
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tetraborate, pH 10 after 30 minutes incubation at room temperature. Each plate contained 
16 negative (0.5% DMSO) and 16 positive (10 µM anacardic acid) controls for a total of 
352 samples per plate. Each sample was reformatted into a single droplet as detailed 
above. Reaction yield based on substrate and product peak area was used for data 
analysis and normalized to positive and negative controls within each row to account for 
variation in reaction yield. Hit compounds were verified by dose-response analysis from 
0.1 to 100 µM (unless otherwise noted on individual plots) and IC50 values were 
calculated from best fit curves using GraphPad Prism 6. 
Results and Discussion 
 Development of a SIRT5 Screening Substrate. Several research groups have 
developed assays for SIRT5, since it was first reported to remove novel protein post-
translational modifications, such as succinyl, malonyl, and glutaryl moieties.88, 92, 94 
Based around fluorogenic substrates,111, 112, 114 these assays are amenable to HTS; but, the 
engineered assay substrates may not always mimic natural substrates well due to their 
short length and the presence of a bulky fluorescent probe near target residues. To avoid 
these limitations, assays based on high-pressure liquid chromatography (HPLC),88 mass 
spectrometry (MS),121 or fluorescence resonance energy transfer (FRET)119 have been 
developed that use short peptides based on natural SIRT5 substrates.  
 In developing our electrophoresis assay, we wanted our peptide substrate to have 
the fluorescent tag remote from the succinyl lysine to reduce potential for false positive 
results, have a total charge suitable for rapid electrophoretic separation of substrate and 
product, and be based on a known SIRT5 target to mimic in vivo substrates. Known 
SIRT5 targets, such as CPS1,99, 100, 103 PDC,98 SDH,98 and HMGCS2,99 as well as 
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hypersuccinylated proteins, such as hydroxyacyl-Coenzyme A dehydrogenase (HADH),98 
acetyl-Coenzyme A acetyltransferase (ACAT),98 and malate dehydrogenase (MDH)99 
were identified as templates for substrate development. We selected a peptide based on 
SDHA K179 due to the favorable peptide charge (-2 for substrate, 0 for product) under 
basic pH used for analysis; although in principle another target could be used for 
substrates if desired. The length was sufficient to provide distance (five amino acids) 
between the 5-FAM tag and the target lysine while providing several amino acids on 
either side of K179 for substrate recognition as demonstrated by other groups.88, 109, 143 
Additionally, total peptide charge was only slightly negative and allowed for short 
migration times and good separation from the product peptide formed after SIRT5 
desuccinylation. 
 Separation of the substrate and product peptides was achieved in 250 ms due to 
favorable charge-to-size ratio, high electric field, and short separation distance (see 
below). Injection of SIRT5 reaction mixture resulted in two peaks in the 
electropherogram associated with the succinylated substrate and desuccinylated product 
peptides (Figure 3-1A). Removal of the succinyl moiety caused a +2 change in peptide 
charge resulting in a faster migration time.  
 To evaluate the quality of our SDHA-derive peptide substrate, we compared the 
activity of SIRT5 and SIRT5H158Y – catalytically inactive SIRT5 – with the peptide 
substrate and full PDC. For the peptide substrate, robust activity, as quantified by product 
peak area, was observed for SIRT5 with only slight activity observed for SIRT5H158Y 
(Figure 3-1A). Likewise incubation of PDC with SIRT5, but not SIRT5H158Y, resulted in 
decreased succinylation of PDHA1 – the catalytic subunit of PDC (Figure 3-1B). 
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Therefore, in terms of SIRT5 activity, our SDHA-derived peptide substrate behaved 
similarly to full PDC. 
 
 
Figure 3-1. SIRT5 and SIRT5H158Y have similar activity against SDHA-derived peptide 
and PDC holoenzyme. (a) Electropherograms demonstrating that SIRT5 desuccinylates 
target peptide forming a product with shorter migration time and that SIRT5H158Y has 
reduced enzymatic activity. (b) Succinylation of porcine heart PDC is reduced following 
incubation with SIRT5 but not SIRT5H158Y. Upper blot: total lysine succinylation; 
PDHA1 band highlighted in red. Middle and lower blots: PDHA1 and SIRT5, 
respectively. 
 Improvements to Sample Throughput for Microchip Electrophoresis. 
Analysis of droplet samples by MCE was done using a hybrid PDMS-glass microfluidic 
device modified from that described previously (Figure 3-2).142 In this system, samples 
stored in a length of Teflon tubing are flowed past the inlet of a fused silica extraction 
capillary inserted into the glass MCE device. As the droplets exit the Teflon tubing, they 
are wicked into the extraction capillary. Once on the microfluidic device they were pulled 
by EOF toward the voltage-gated injector for MCE analysis. A combination dead volume 
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in the extraction capillary and separation speed limited the system throughput. In this 
work, we examined improving the throughput to enable larger scale screens. 
 
 
Figure 3-2. Schematic of microfluidic device for analysis of droplet samples by MCE 
showing positioning of droplet samples orthogonally to the 1 mm fused silica extraction 
capillary.  
 In the original system, the extraction capillary had a 3.1 nL volume (2.5 mm 
length x 40 µm i.d.). To effectively clear this dead volume, 16 nL of sample (2 droplets 
of 8 nL each) was required. The time required to perform this rinse limited assay 
throughput to 0.16 samples per second. For these experiments, the device was redesigned 
to accommodate a 1 nL extraction capillary (1 mm length x 30 µm i.d.). We found that 
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with this volume a single 8 nL droplet provided a sufficient rinse of the extraction 
capillary allowing throughput to be increased 2-fold relative to the previous 
implementation.  
 Although reduced dead volume increased sample throughput, separation speed 
remained a bottleneck. In previous work, separation distance was 5 mm and electric field 
was 2000 V/cm. Using these conditions, rhodamine, substrate, and product for SIRT5 
assays were resolved within 1 s (Figure 3-3A). Resolution could be maintained at shorter 
times by reducing detection length and increasing the field (Figure 3-3A). The fastest 
separation achieved was 250 ms at 3500 V/cm and 2 mm separation distance.  
 At the high field and short separation length, over injection led to poor resolution. 
To determine the best injection time, peak variance for substrate and product peptide was 
measured for injection widths of 10 ms to 35 ms (Figure 3-3B). A minimum peak 
variance was observed at 15 ms injection width for both substrate and product peptides 
and was used for all future separations. Under these conditions, the average separation 
efficiency for three analytes was 7,000 ± 1,000 plates. When corrected for analyte 
migration time, the separation generated 41,000 ± 8,000 theoretical plates/s. These 
conditions allowed 4 injections/s so that 8 injections were obtained per droplet and 
sample throughput was 0.5 Hz. This result is a 3-fold increase in sample throughput 
compared to the previous design.142  
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Figure 3-3. Separation throughput was increased 4-fold for SIRT5 assay through 
improvement of separation and injection conditions. (a) Electropherograms for initial 
separation conditions based on previous work and improved conditions capable of 
baseline separation in as little as 250 ms. (b) Optimum injection width is 15 ms based 
substrate (black) and product (red) peak variance. 
 The high rate of injections allowed monitoring of when carryover was eliminated 
(typically 3 injections) and collection of at least 3 replicate assays per droplet. Carryover 
was determined by monitoring the presence or absence of a rhodamine signal (rhodamine 
was present in every other droplet) and stability of peak height for substrate and product 
peaks in the electropherogram.    
 An important consideration is whether the electropherograms are stable over 
many injections. Migration time RSD for rhodamine, substrate, and product were 1.3%, 
0.7%, and 0.6%, respectively (n = 1400). Additionally, peak areas were stable over many 
injections. For samples containing rhodamine, peak area RSD was less than 5% for 
replicate injections of the same sample (n = 3) and average rhodamine peak area RSD 
was 6% over 88 samples (n = 264 injections). This corresponds to one batch of samples 
(e.g. 88 samples with rhodamine and 88 without). Slight changes in peak magnitude were 
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observed from batch to batch, but this did not affect data quality because peak area ratios 
were used for analysis (Figure 3-4). Substrate and product peak area fluctuated from 
sample to sample due to slight variation in enzyme efficiency; however, peak area RSD 
was less than 5% for replicate injections of the same sample (n = 3). 
 
 
Figure 3-4. Representative electropherograms from injections made at the beginning (a) 
and end (b) of SIRT5 screening. The compound number is labeled above injections, 
which are denoted by an arrow. Individual peaks corresponding to rhodamine (R), 
product (P), and substrate (S) are labeled. 
 SIRT5 Inhibitor Screening. The assay for SIRT5 monitored the depletion of 
substrate peptide (5-FAM-GGQSLK[succ]FGKG) and formation of product peptide (5-
  57 
FAM-GGQSLKFGKG) simultaneously (Figure 3-5A). Reaction yield was normalized to 
positive and negative controls within each row of the well plate and plotted as normalized 
SIRT5 activity for each sample. Monitoring two analytes and normalizing to row controls 
mitigated the effect of variation in sample preparation, injection, or separation efficiency 
over the course of screening. Samples were indexed by addition of rhodamine 110 to 
even number samples and monitoring changes in rhodamine peak area to identify samples 
as previously demonstrated.142 Prior to screening, substrate concentration for screening 
was determined from kinetics data. Based on Michaelis-Menton kinetics, the Km (1.6 ± 
0.4 µM) and Kcat/Km (5.8 x 104 M-1s-1) values were determined (Figure 3-5B). These 
match well with reported values for SIRT5 substrate peptides of similar length based on 
Histone H3 (Km = 5.8 ± 2.7 and Kcat/Km = 4.3 x 103 M-1s-1)88 and CPS1 (Km = 3.8 ± 0.6 
and Kcat/Km = 1.4 x 104 M-1s-1).109 Reaction progress was linear up to 50 minutes, the 
longest point tested (Figure 3-5C). Addition of 1.5 volumes of 10 mM sodium 
tetraborate, pH 10 completely inactivates SIRT5 (Figure 3-5D). To satisfy screening 
assay requirements2, 144 substrate concentration was fixed at 1 µM, below the Km, and 
reactions were quenched after 30 minutes. 
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Figure 3-5. A) SIRT5 catalyzes the removal of succinyl moieties from lysine side chains 
in the presence of NAD+ causing a +2 change in peptide charge. B) Michaelis-Menton 
kinetics data for SIRT5 with excess NAD+. Km is 1.6 ± 0.4 µM, Kcat is 0.092 ± 0.008 s-1, 
and Kcat/Km is 5.8 x 104 M-1s-1. C) Reaction progress for 1 µM substrate and 10 nM 
SIRT5 demonstrating reaction linearity up to ~50 minutes. D) SIRT5 reaction can be 
quenched by addition of 1.5 volumes of 10 mM sodium tetraborate, pH 10. Ice sample 
was quenched after 30 minutes and stored at -80 °C, RT sample was quenched after 30 
minutes and stored at room temperature, and 1 hr sample was allowed to react for 1 hr 
before quenching. (n = 3 for all samples). 
 To validate reaction conditions for high throughput screening, SIRT5 activity was 
screened against a library of 80 compounds from an epigenetics focus library known to 
inhibit other members of the sirtuin family (Figure 3-6A). Each test compound was 
screened at 10 µM. Seven compounds were identified as SIRT5 inhibitors, based on a 50 
percent inhibition of SIRT5 activity. These hits were verified with dose-response curves 
and IC50 values ranged from 60 nM to 8 µM (Figure 3-6B). Of the compounds, suramin 
has previously been reported as a SIRT5 inhibitor in NAD+-nicotinamide exchange 
assays (IC50 = 22 µM)89 and fluorogenic assays (IC50 = 47 µM).145 AGK-2 has been 
reported as a SIRT5 inhibitor with an IC50 value above 100 µM.108 The difference in IC50 
values may be due to these assays focusing on SIRT5 deacetylase activity, which is much 
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lower than SIRT5 desuccinylase activity, or differences in assay conditions. The potent 
inhibitor anacardic acid was chosen as a positive control for future screens based on the 
results of pilot screening. 
 
 
Figure 3-6. A) Data from SIRT5 assay validation screen using 80 compounds from the 
Epigenetics Screening Library. Inhibition threshold is denoted by red line. B) Dose-
response curves for compounds reducing SIRT5 activity by 50 percent. 
 These validated conditions were used to screen the Prestwick Chemical Library, 
which contains 1280 approved drug compounds, against SIRT5 (Figure 3-7A). Reactions 
were prepared in 384-well plates using high-throughput sample preparation 
instrumentation for incorporation into existing HTS workflows. Each of the 1408 samples 
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(1280 compounds, 64 positive controls, and 64 negative controls) were reformatted into a 
single droplet with an average volume of 8.2 ± 0.3 nL (n = 352) at 0.75 Hz (although 
faster reformatting is possible146). Analysis was done in batches of 176 samples, 
corresponding to one-half of a plate, with a sample throughput of 0.5 Hz. Total analysis 
time was 46 minutes and generated over 11,000 electropherograms at 8 injections per 
sample (Figure 3-7B). The assay Z’-factor, when corrected for row effects caused by 
sample preparation, was 0.8. 
 
 
Figure 3-7. Screen of Prestwick Collection Library against SIRT5. A). Normalized 
SIRT5 activity with each of the 1280 compounds. Each point represents the average 
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enzyme activity with a test compound and the red line denotes the inhibition threshold. 
B) Top plot: Electropherograms corresponding to the 160 compounds in the grey region 
of Panel A. Bottom plot: Enlarged view of red highlight region (338-342 s) showing 
separation of rhodamine (R), product peptide (P), and substrate peptide (S) for three 
compounds. #1117 is an inhibitor. Injections are denoted with an arrow and 6-8 injections 
are made from each sample droplet. 
Among the compounds, 10 reduced SIRT5 activity by 70 percent and were 
selected for further study. At the time of initial screening, all reactions containing SIRT5 
inhibitors were re-formatted as duplicate droplets and analyzed by MCE to confirm 
results (Figure 3-8). These compounds were evaluated for dose-dependent SIRT5 
inhibition and 8 were confirmed as SIRT5 inhibitors. The remaining two compounds did 
not exhibit dose-dependent inhibition of SIRT5 and were identified as false positives 
caused by sample preparation.  
 
 
Figure 3-8. Confirmation of SIRT5 inhibitors during initial screening and demonstration 
of analysis reproducibility. All compounds identified as reducing SIRT5 activity by 70 
percent were formatted into two sample droplets each and re-analyzed by MCE. In all 
cases, the data from re-testing (red bars) matches well with initial screening (black bars) 
data demonstrating reproducibility of analysis and confirming SIRT5 inhibitors for 
follow up studies. Compounds labeled with an asterisks (*) were identified as false-
positives by dose-response analysis (i.e. dose-dependent inhibition was not observed). 
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All dose-response curves had good fit (R2 >0.90) except antimycin A, which had 
an IC50 value near the maximum tested dose (Figure 3-9). (See Appendix B for dose-
response fit values and structures of confirmed inhibitors.) The calculated IC50 values are 
in the low micromolar range matching the most potent reported SIRT5 inhibitors.108, 109, 
147 None of the compounds have previously been reported as SIRT5 inhibitors; however, 
SIRT5 was reported as a potential target of probucol based on molecular targeting and 
docking studies.148 
 
 
Figure 3-9. Dose-response analysis for compounds reducing SIRT5 activity by 70 
percent. Ten compounds were identified during screening and 8 were confirmed as 
inhibitors with IC50 values denoted on each plot. 
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 Future Improvements to sample throughput and robustness. If run 
continuously, the current system could analyze over 14,000 samples in 8 hours; however, 
even higher throughput may be possible with further improvement. For example, the 
current separation speed was limited by peak resolution between rhodamine and product 
peptide, while the resolution between product and substrate is 2.5. If rhodamine – used 
for sample indexing – was replaced by a more positively charged analyte with faster 
migration velocity, then separation time could be further reduced without loss of baseline 
resolution. For example, reducing separation time to 125 ms (half of the current 
separation time) could increase sample throughput to 1 Hz (>28,000 samples in 8 hours). 
Additional throughput could be achieved by testing multiple compounds 
simultaneously.149 While additional assays would be needed to de-convolute any 
inhibitors or synergistic inhibition effects, throughput would increase linearly with the 
number of compounds per reaction. 
 Although we have demonstrated an assay for SIRT5 capable of screening a meso-
scale compound library, several factors limit using droplet samples for routine analysis. 
Several steps during sample analysis require making zero dead volume connections with 
small flexible tubing, which can be difficult and is labor intensive. During droplet 
formation, the number of droplets that can be formed reproducibly is limited by back 
pressure from droplet samples within the collection tubing. This limits read length to 
several hundred samples requiring batch analysis for large libraries. Although generating 
droplets in parallel is possible, it increases complexity and requires additional low dead 
volume connections.146 If droplets could be generated and analyzed continuously, then 
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analysis limits imposed by low dead volume connections and droplet read length could be 
mitigated. 
Conclusion 
 In this work, we have described a SIRT5 screening assay based on ultrafast 
electrophoresis using nanoliter volume samples suitable for meso-scale library screening. 
A novel SIRT5 substrate derived from SDHA was developed to achieve rapid separation 
of substrate and product, while avoiding several limitations associated with commercially 
available fluorogenic substrates. Using this assay, 1408 samples (1280 compounds, 128 
controls) were screened against SIRT5 and 8 previously unknown SIRT5 inhibitors were 
identified. Analysis was completed within 46 minutes (0.5 Hz) and over 11,000 MCE 
injections were made demonstrating method speed, robustness, and reliability. Under 
these conditions, throughput was increased 3-fold relative to previous MCE-based 
screening and 25-fold compared to previous sirtuin screens by MCE or CE.  
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CHAPTER 4:  TOWARD AN ALL-DROPLET MICROCHIP 
ELECTROPHORESIS SCREENING PLATFORM 
Introduction 
Over the past few decades, high-throughput screening (HTS) has become a vital 
tool for drug discovery within the pharmaceutical industry.1, 2 As it has gained popularity, 
the scale of HTS has increased to encompass libraries containing hundreds of thousands 
of compounds. To mitigate the rising cost of screening such large libraries,61, 150 plate 
densities have increased and assay volumes have decreased. Although assay volume can 
be as low as several microliters, a typical assay of 106 compounds requires several liters 
of each reagent. These volume requirements are prohibitive when screening rare, difficult 
to express, or expensive enzymes. Further increasing the plate density (i.e. 6144-well 
plates) requires sub-microliter sample volumes; however, customized liquid dispensing 
methods are necessary and sample evaporation is common.151, 152 Therefore, alternate 
strategies for miniaturizing HTS assays are necessary. 
Droplet microfluidics has emerged as a powerful tool for handling and 
manipulating low volume samples and provides an interesting solution for decreasing 
sample volume in high-throughput screening.53, 60, 62-64 In droplet microfluidics, aqueous 
samples, typically picoliter to nanoliter in volume, are encapsulated within an immiscible 
phase and manipulated within microfluidic devices.27 Because carrier fluid, typically air 
  66 
or fluorinated oil, surrounds sample droplets, evaporation is significantly reduced. A 
range of droplet transformations are possible, such as mixing,48-52 reagent addition,27, 38, 
50, 52, 57, 58 dilution,59, 60 splitting,39-42 and sorting,35, 53, 54, 56 to achieve complete analysis 
within a miniaturized format. In one example, the authors deposited nanoliter volume 
droplets in a 2D array on a flat surface and covered them with an oil layer.153 In this 
manner, they could add reagents and sample from nanoliter volume droplets without 
sample evaporation.154, 155 Using these methods sample consumption could be reduced by 
more than 1,000-fold relative to conventional assays.53  
Accurate reagent dispensing is necessary to reduce sample-to-sample variability 
and to achieve high-quality screening results. Several reagent addition systems for droplet 
microfluidics have been developed based on active and passive methods. Active methods, 
such as electrocoalescence156-159 or the thermocapillary effect,160 provide robust operation 
and are able to selectively add reagents to some droplets but not others. However, they 
require external input to control reagent addition and have more complicated operation. 
Passive devices, on the other hand, afford simpler operation but are unable to add 
reagents on only certain droplets (e.g. cell sorting applications) and performance is 
dependent on reagent composition (e.g. organic content and surfactants).38, 52, 57, 58 One 
group reported the use of PDMS reagent addition devices with hydrophilic reagent 
channels to achieve robust operation for blood coagulation assays, but droplets were 
entirely manipulated within the device and carryover was not detailed.52 Another group 
built upon this design, using PVDF and HFPA+ tubing, and demonstrated low carryover 
reagent addition to droplets from in vivo sample probes and screening assays.38, 58 
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Although robust operation was reported, a single reagent inlet and complicated 
fabrication procedure limit widespread use. 
In this work we demonstrate a simple and robust PDMS device for passive 
reagent addition was developed using single layer SU-8 fabrication. The high sample 
throughput, simple operation, and low carryover are demonstrated in several fundamental 
experiments. Samples prepared using the reagent addition device were analyzed using 
microchip electrophoresis to demonstrate progress toward all-droplet screening assays. 
Materials and Methods 
Chemicals and Materials. Unless otherwise specified all reagents were 
purchased from Sigma Aldrich (St. Louis, MO). PDMS devices were fabricated from 
degassed RTV-615 (Momentive, Inc., Waterford, NY) using a base to curing agent ratio 
of 10:1. Fluorescent peptide (5-FAM-GGQSLK[succ]FGKG) was purchased from 
GenicBio Ltd (Shanghai, China). 
Microfluidic Device Fabrication. Reagent addition devices were fabricated in 
PDMS using standard soft lithography.42, 161 Briefly, HMDS was spun onto a 3-inch 
silicon wafer (University Wafer, Boston, MA) to promote photoresist adhesion. SU-8 
2075 photoresist (MicroChem, Corp., Newton, MA) was spun onto the wafer to achieve a 
110-µm deep layer. Wafers were baked (5 min at 65 °C and 15 min at 95 °C) prior to UV 
light exposure (Optical Associates, Inc., Malpitas, CA) through a photomask to cross-link 
features. After exposure, wafers were baked (3 min at 65 °C and 8 min at 95 °C) prior to 
developing in SU-8 photoresist developer (MicroChem, Corp., Newton, MA). After 
fabrication, droplet channels were 110 µm wide and reagent inlets were 100 µm wide. 
After casting PDMS over the molds, devices were trimmed to size and bonded to 
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unpatterned PDMS using plasma oxidation. Sealed devices were placed on a hot plate (75 
°C) for 5 minutes to enhance bonding prior to surface functionalization. After 
functionalization, reagent capillaries (40 µm i.d. x 150 µm o.d.) were inserted into 
reagent inlet channels to be flush with the droplet channel. Derivatized transfer capillaries 
(100 µm i.d. x 150 µm o.d.) were inserted as needed to facilitate sample transfer. 
Capillaries were adapted to 360 µm fittings by gluing a 1 cm length of 180 µm i.d. x 360 
µm o.d. capillary or 150 µm i.d. x 360 µm o.d. HFPA+ tubing at one end. 
Fluorophilic derivatization of PDMS and fused silica. For PDMS devices, 
channels were derivatized by filling with 1H,1H,2H,2H-perfluorooctyltrichlorosilane (4% 
v/v in anhydrous hexadecane) for 10 min.42 Devices were rinsed by sequential perfusion 
with hexadecane and hexane prior to baking at 80 °C overnight. Fused silica capillary 
was derivatized based on a previously reported method.22 Briefly, the fused silica 
capillary was flushed with 1 M sodium hydroxide (10 min) and water (10 min) at 25 
µL/min to activate surface silanols. Capillaries were purged with nitrogen (30 psi) at 90 
°C for 1 hr to remove any remaining water. The surface was derivatized by perfusion 
with 1H,1H,2H,2H-perfluorooctyltrichlorosilane (5% v/v in toluene) at 90 °C for 2 hr at 
25 µL/min. Capillaries were rinsed with toluene and methanol (30 min at 25 µL/min) 
before drying under nitrogen (30 psi) for 3 hr at 90 °C. 
Droplet Reagent Addition. Prior to experiments, reagent addition devices were 
primed with carrier fluid (200:1 perfluorodecalin:perfluorooctanol) to coat PDMS 
surfaces. At the beginning of experiments, transfer capillaries were primed for 5 min 
under experimental conditions to remove any air bubbles and ensure stable flow. Sample 
droplets were generated via tee junction (throughput experiments)32-34 or sipping from a 
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multiwell plate (carryover and electrophoresis experiments).35-38, 142, 146 Reagents could be 
added at 10 to 30 percent of parent droplet volume by controlling relative flow rates via a 
syringe pump (Chemyx Inc, Stafford, TX). Droplet signal was monitored by laser-
induced fluorescence or extracted from movies using frame-by-frame analysis in ImageJ. 
Droplet Analysis by Microchip Electrophoresis. For demonstration of coupling 
reagent addition to MCE analysis, sets of droplet samples containing either fluorescent 
dye or water were analyzed as previously described.142 All parameters were identical 
except for droplet flow rate during extraction, which was increased to 1000 nL/min to 
account for two droplets per sample. Sample droplets with average volume of 3.6 ± 0.3 
nL (n = 60) were generated from a multiwell plate to consist of alternating sets of two 
droplets containing either rhodamine or water in 0.5% DMSO (i.e. R-R-W-W, etc.). A 
fluorescent peptide (8 µM in 80 mM Tris, pH 8) was added to mimic reagent addition 
conditions during HTS. Flow rates were controlled so that 0.6 nL of reagent was added to 
each droplet. 
Results and Discussion 
To significantly reduce sample consumption for HTS and to enable screening of 
rare or hard to purify enzymes, this work proposes to perform all aspects of sample 
preparation within nanoliter volume samples. The workflow for analysis consists of three 
steps: droplet generation, reagent addition, and analysis (Figure 4-1). In most high-
throughput analysis facilities, test compounds are arrayed in 96- or 384-well plates for 
rapid dispensing. Therefore, starting droplets will be formed from compound libraries 
into a series of test compound droplets. After formation, test compound droplets will be 
pumped through a microfluidic device to inject picoliter volumes of assay reagents into 
  70 
each droplet and allow reaction incubation. Finally, sample droplets can be analyzed by 
MCE to determine test compound efficacy. Several groups have reported methods for 
generating droplets. Therefore, this work will focus on addition of assay reagents and 
analysis by MCE. 
 
 
Figure 4-1. Overview of all-droplet high-throughput screening with microchip 
electrophoresis for detection. Droplets containing test compounds are generated by 
sipping from an MWP. Reagents (e.g. substrate and enzyme) are directly injected into 
droplets using a PDMS microfluidic device and collected for incubation. Completed 
reactions are analyzed by MCE and inhibitors are identified based on amount of substrate 
and product present in each sample. 
Reagent Addition Device Design and Operation. To perform HTS entirely 
within droplet format, reliable addition of reagents to each droplet is necessary. Several 
methods exist for adding reagents, but the simplest utilize direct injection of reagents into 
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passing droplets at tee junction. Several groups have developed these devices in various 
formats with the common attribute being the use of hydrophilic channels for reagent 
delivery.52, 57 Although these devices demonstrated reliable operation within the 
parameters necessary for HTS, they were either difficult to fabricate38, 58 or were 
demonstrated to be compatible with sample droplets formed off of the device.52, 57 
To address these limitations, we developed a single layer PDMS device for 
reagent addition using these existing devices as a design guide. The device consists of a 
tee junction in which the outlet of a fused silica capillary can be oriented flush with the 
PDMS droplet channel (Figure 4-2). The design is scalable so that several reagents can be 
added sequentially within a single device by incorporating additional reagent channels 
similar to existing PDMS reagent addition devices. Additionally, serpentine channels 
were integrated to facilitate rapid mixing of reagents. We found that using narrow bore 
reagent capillaries, typically 40 µm i.d. x 150 µm o.d., reduced sample carryover due to 
lower diffusional mixing as a result of high linear flow rate at the outlet. At smaller inner 
diameter (e.g. 20 µm i.d. x 150 µm o.d.), the increased surface area of fused silica, due to 
thicker capillary walls, caused droplet sticking and increased carryover. This effect could 
be mitigated by either derivatizing the tip of the reagent capillary or using a capillary 
with smaller outer diameter, such as 20 µm i.d. x 90 µm o.d., which would reduce the 
hydrophilic surface area of the capillary. 
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Figure 4-2. Schematic of PDMS droplet reagent addition device. Sample droplets 
containing test compounds are pumped onto the chip through a fluorinated capillary 
while reagents are injected via hydrophilic capillaries. Serpentine mixing regions on the 
device rapidly distribute reagent throughout the droplet. Droplets are collected via 
another fluorinated capillary for incubation or analysis. 
One of the biggest challenges for reagent addition into preformed droplets is 
transferring sample droplets onto the device without droplet breakup. We chose to use a 
fluorinated fused silica capillary (100 µm i.d. x 165 µm o.d.) to transfer droplets onto the 
device (Figure 4-2). Due to the larger cross section, the capillary stretches the PDMS 
channel forming a tight seal to prevent leaking. Droplet samples transition from capillary 
to chip without sticking due to he similar dimensions for the capillary and channel. 
Because most fittings are designed around 360 µm tubing, the transfer capillary was 
adapted by inserting one end into a length of HFPA+ tubing (150 µm i.d. x 360 µm o.d.). 
This allowed for zero dead volume connections to droplet storage tubing using a Teflon 
connector (Figure 4-3). 
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Figure 4-3. Image of zero dead volume Teflon union used to connect Teflon tubing 
containing sample droplets (left side of image) to the fluorinated transfer capillary. 
Droplets seamlessly transfer from Teflon-Teflon and from Teflon-capillary with minimal 
carryover. 
Oil phase surfactant (e.g. perfluorooctanol) plays an important role in reagent 
addition by stabilizing droplets to reduce carryover. However, high surfactant 
concentrations will overly stabilize droplets and prevent reagents from being added. To 
determine an acceptable surfactant concentration, reagent addition stability was 
monitored for experiments using 0-1 % perfluorooctanol as a surfactant. When surfactant 
concentration was greater than 1 %, coalescence of the reagent stream into the droplet did 
not occur and reagent only droplets were formed (Figure 4-4A). When the surfactant 
concentration lowered to 0.5 %, successful reagent addition was observed for every 
droplet (Figure 4-4B). As the concentration was further reduced to 0 %, reagent addition 
was successful, but carryover was increased (Figure 4-4B). We hypothesize that at low 
surfactant concentrations, diffusional mixing between the reagent stream and passing 
droplet leads to increased carryover. Conversely, at high surfactant concentration the 
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droplet interface is stabilized and merging with reagent streams does not occur leading to 
formation of reagent only droplets. Therefore, surfactant concentration was fixed at 0.5 % 
v/v to provide low carryover and robust reagent addition. Under different conditions, for 
example high organic content, increased surfactant concentration may be necessary to 
stabilize droplets and reduce carryover. 
 
 
Figure 4-4. Effect of oil phase surfactant concentration on reagent addition and 
carryover. A) At high surfactant concentration (1 %), reagent droplets do not completely 
merge with passing droplets leading to formation of reagent only droplets. B) At low 
surfactant concentrations, reagent droplets readily merger with passing droplets. 
However, carryover increases, slightly, as surfactant concentration approaches 0 %. 
Characterization of Reagent Addition Throughput and Stability. In HTS, the 
sample throughput directly correlates to total analysis time and operating at maximum 
sustainable throughput is beneficial. For compatibility with various analysis methods, our 
reagent addition device should operate across a range of sample throughputs. To test 
speed and reproducibility of reagent addition, a dual tee device was fabricated, which 
allowed formation of and reagent addition into droplets on a single device. The size 
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droplets and rate of reagent addition was extracted from high-speed video and reagent 
flow rate was maintained so that 10 percent of the parent droplet volume was added 
regardless of the droplet flow rate. 
As expected, the rate of reagent addition increases linearly with droplet flow rate 
(Figure 4-5). At a droplet flow rate of 1 µL/min, reagent addition occurs at approximately 
1 Hz and increases linearly up to the fastest flow rate tested. However, at high flow rates, 
reagent addition become unstable and reagent was not added to every droplet. This is 
likely due to the low dwell time at the reagent capillary and imprecision in flow rate 
caused by the syringe pumps. Droplet intensity was measured to ensure a similar amount 
of reagent was added regardless of sample throughput. Based on analysis of 1 min videos 
at each flow rate, normalized droplet intensity RSD was less than 5 percent across all 
flow rates (Figure 4-5).  
 
 
Figure 4-5. Reagent addition throughput increases linearly with droplet flow rate up to 3 
µL/min (the fastest flow rate tested). At each flow rate, reagent flow rate was adjusted to 
achieve 10 percent addition into the parent droplet. Normalized droplet intensity, a 
measure of reagent addition reliability, is consistent across the flow rates tested. 
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Measurement of Carryover During Transfer and Addition. Whereas previous 
demonstrations of reagent addition utilized continuous signal changes (i.e. in vivo 
perfusate58 or continuous blood perfusion52), HTS often has discrete signal changes from 
sample to sample. Therefore, carryover must be minimized at each step of reagent 
addition to maintain a high assay quality. Device carryover was monitored a three points 
during reagent addition to quantify where carryover occurs: transfer of droplets onto the 
device, first reagent addition, and second reagent addition. To quantify carryover, sets of 
droplets containing a signal droplet (rhodamine) and four blank droplets were generated. 
At the first reagent inlet, assay buffer was added (80 mM Tris, pH 8, 8 mM DTT) and 
enzyme buffer (10 mM sodium phosphate, pH 8, 100 mM sodium chloride, 0.01% Tween 
20, 15% glycerol) was added at the second reagent inlet. If carryover is zero percent, one 
expect no signal from blank droplets and any signal in blank droplets can be considered 
carryover caused by reagent addition. 
During the transfer step, sample droplets are transferred from the collection tubing 
into a transfer capillary and then onto the PDMS device with minimal carryover (Figure 
4-6). The first blank droplet had 0.12 ± 0.04 percent carryover and subsequent blank 
droplets had 0.01 ± 0.05 percent carryover. This low carryover is made possible by the 
use of zero dead volume connections and the similar size of the transfer capillary and 
PDMS channel. More significant carryover is observed after the first reagent is added. 
However, the cumulative carryover is sequestered in the first blank droplet (2 ± 1 
percent) whereas the second blank had negligible carryover (0.03 ± 0.1 percent). After 
the second reagent addition, cumulative carryover in the first droplet had increased to 5.5 
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± 0.3 percent, but carryover remained low in the second blank droplet (0.5 ± 0.3 percent). 
These data suggest that for best results, two droplets should be used per sample. 
 
Figure 4-6. Plot of reagent addition carryover in the first and second blank sample at 
each step of reagent addition. Most carryover is contributed by addition of reagents with 
reagents containing glycerol and Tween leading to higher carryover. At all steps, 
carryover is less than 1 percent in the second blank sample suggesting that two droplet 
per sample should be sufficient to avoid carryover during analysis. The droplet train 
consisted of alternating sets of a signal droplet followed by four blank droplets (e.g. S-W-
W-W-W). In all cases, the last two blank droplets had no carryover. 
The increased carryover observed for the second reagent could be due to the 
presence of 15 % glycerol and 0.01 % Tween 20 in the reagent. Both of these buffer 
components are necessary to prevent enzyme adsorption, but increase the wettability of 
the PDMS surfaces leading to increased carryover. However, these values match well 
with reported carryover for a device fabricated from HFPA+/PVDF in which carryover in 
the first droplet was ~5 percent and was reduced to less than 1 percent in subsequent 
droplets.38 
In addition to carryover caused by reagent addition carryover could occur if 
analytes partition from the droplet into the oil phase. Once in the oil phase, the analyte 
  78 
could then partition into adjacent droplets leading to artificial results.162 Although it is 
generally accepted that fluorinated oil phases prevent sample-to-sample contamination, 
the use of non-fluorinated oils (e.g. mineral oil) or inclusion of oil phase surfactants (e.g. 
RainDance EA-surfactant) results in formation of reverse micelles that can transport 
analyte from one droplet to another through the carrier fluid.163, 164 In most cases, this 
migration occurred over the course of several hours or when using fluorescent dyes. For 
HTS, many substrates are peptide-based and the peptide sequence can be optimized ot 
sequester analytes within droplets (i.e. many hydrophilic residues). Additionally, in 
droplet incubation times are typically much less than 1 hr for HTS and analyte migration 
should be minimal. However, further investigation is required to quantify this effect when 
using perfluorodecalin:pefluorooctanol as an oil:surfactant phase. 
Coupling Reagent Addition Samples to MCE Analysis. To demonstrate the 
utility of all-droplet sample preparation for high-throughput analysis, sample droplets 
were coupled to microchip electrophoresis for analysis. Preformed droplets contained 
either water or rhodamine and fluorescent peptide was directly injected using the reagent 
addition device. In order to mimic assay conditions, samples were collected into HFPA+ 
tubing and allowed to ‘incubate’ for 30 min before being analyzed by MCE as described 
previously.142 
Due to the on chip dead volume and carryover within the first droplet of each 
sample, peak heights for rhodamine and peptide do not stabilize until the second droplet 
as observed by MCE (Figure 4-7A). Because each sample is comprised of 2 droplets, 8 
replicate injections are made from each droplet and sample throughput is 0.33 Hz. This 
approach, which lowers throughput from the maximal possible, is necessary to ensure at 
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least 3 replicate injections are made from the second sample droplet where carry-over is 
low.  
During HTS, raw data is converted to a reaction yield to quantitate test compound 
efficacy and quickly identify compounds that inhibit enzyme activity. To mimic this data 
transformation and demonstrate that reagent addition does not affect data quality, the 
peak area ratio between rhodamine and fluorescent peptide was used for analysis. 
Furthermore, the average peak area ratio for water and rhodamine containing droplets 
was used to normalize data. For droplets containing only water, the normalized peak area 
ratio is 0, because only a peptide peak is observed in the electropherogram. For 
rhodamine containing samples, both rhodamine and peptide peaks are observed in the 
electropherogram resulting in a normalized peak area ratio of 1. If significant carryover 
were observed for either sample type, the peak area ratio would begin to deviate 
significantly from these values and a rhodamine peak would be observed in 
electropherograms from water droplets (Figure 4-7B). 
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Figure 4-7. Demonstration of coupling reagent addition sample preparation to microchip 
electrophoresis for analysis. (A) Selected raw electropherograms from the analysis of 
alternating sample sets (two droplets each) demonstrating that carryover is present in the 
first droplet but is not present in the second sample droplet. Arrows denote MCE 
injections and the rhodamine (R) and peptide (P) peaks are labeled in each separation. (B) 
Plot of normalized peak area ratio (rhodamine:peptide) from samples containing either 
rhodamine or water. The shaded regions denote ± 1 standard deviation for the average 
peak area ratio of each sample type. 
Conclusion 
We have demonstrated the several aspects of an all-droplet high-throughput 
screening platform using microchip electrophoresis for biochemical assay screening. We 
designed a simple PDMS device to allow direct injection of reagents into preformed 
nanoliter volume droplets. Carryover during the reagent addition steps matches closely to 
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previously published results for a more complicated device. Sample throughput was 0.33 
Hz allowing at least 3 replicate MCE injections from the second droplet with negligible 
carryover during analysis. This platform should allow for routine sample preparation in 
droplet format allowing a 1,000-fold reduction in reagent consumption. Although this 
project demonstrates technological improvements toward all-droplet assays, the lack of 
widespread adoption is likely due to a number of factors. These factors range from the 
need to optimize conditions (i.e. oil phase and surfactant concentration) for each sample 
type, the inability to retest samples without repeating the assay, and the inability to 
perform continuous operation due to limitations on the number of droplets that can be 
reliably formed.  
Another limitation to widespread adoption is the challenge of forming distinct 
droplets containing test compounds of interest. This work couples droplets to existing 
MWP libraries to achieve this task; however, it is relatively low throughput and requires 
libraries be organized in well plates. An alternative strategy would be to use bead-based 
chemistry to sequester test compounds and dispense them into droplets as a 
suspension.165 The authors demonstrated dispensing beads loaded with a small molecule 
at up to 10 Hz and exposure to UV radiation disperses the molecule into the droplet. 
Using this method, a barcoded, bead-based library containing small molecules could be 
rapidly formatted into droplets to significantly increase the speed of library formation for 
droplet-based HTS. 
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CHAPTER 5:  FUTURE DIRECTIONS 
In this dissertation, the utility of ultrafast electrophoresis coupled to droplet 
samples for HTS has been described. Although these efforts have demonstrated the 
throughput necessary for HTS, batch analysis and manual connections limit widespread 
use. Therefore, automated droplet formation and continuous device operation are 
desirable. The general principle of mobility shift assays for screening could be applied to 
other pharmacological targets, such as protein-protein interactions. Lastly, nanoliter 
volume sample introduction has to potential to greatly reduce sample requirements for 
other separations based analyses, such as electrochromatography or gel electrophoresis.  
Automated and Continuous Droplet Generation 
One of the limitations for widespread adoption of droplet-based HTS is the 
difficulty with continuous operation. Due to back pressure issues, only several hundred 
droplets can be formed reliably requiring large compound libraries to be analyzed in 
small sections. In batch analysis mode, continuous operation is only possible if one set of 
droplets is analyzed while the next is being formed. Inherent to this type of analysis is the 
requirement for making repeated low dead volume connections, which can be difficult 
and time consuming. To reduce the number of necessary connections and to achieve the 
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maximum analysis throughput, droplets should be continuously generated on-line. This 
could be achieved through a pressure or magnetic driven peristaltic pump. 
Peristaltic pumps are used routinely for liquid dispensing in continuous phase 
systems. In these pumps, two to six ‘rollers’ are attached to a rotor and compress a 
flexible tubing cause liquid to flow. As the rollers rotate, the tubing is alternately 
compressed and released generating a consistent flow rate correlated to the rotor speed. 
Commercially, this has been developed as the HyperCyt autosampler (IntelliCyt Corp., 
Albuquerque, NM) used for rapid sample introduction to flow cytometers (Figure 5-1).166 
In the design, samples are arranged in a MWP and reformatted into air-segmented 
droplets for serial analysis. The sample tubing passes through a peristaltic pump allowing 
continuous operation by generating suction at the inlet and pressure at the outlet. The 
system is capable of 0.67 samples per second (2 µL samples) with less than 2 percent 
carryover. Continuous sample analysis should be possible, with very little modification, 
by coupling a HyperCyt autosampler directly to the inlet of an MCE device or mass 
spectrometer. Under these conditions, the operator would simply need to switch out 384 
well plates every 10 minutes or a robotic plate handler could be used to achieve complete 
automation. 
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Figure 5-1. Schematic of the HyperCyt platform for high-throughput flow cytometry. A 
sample probe is translated around an MWP using a computer controlled positioner while 
air segmented droplets are generated using a peristaltic pump to generate flow.166 
Reproduced with permissions from Nature Publishing Group. 
Alternatively, the carrier phase could be replaced with a magnetic ionic liquid 
(MILs).167-169 MILs are a sub-class of ionic liquids – room temperature molten salts – that 
incorporate high spin transition metals making them susceptible to external magnetic 
fields. If the oil or air carrier phase was replaced with an MIL, an external magnetic field 
could be used to generate flow within the tubing.170 For example, several ring-shaped 
electromagnets could be placed in a series along the droplet tubing. By energizing them 
in a wave pattern, a traveling magnetic wave could be generated within the droplet tubing 
creating bulk flow of the magnetic ionic liquid. Because the aqueous samples are 
dispersed in series within the ionic liquid, they would be dragged along. Assuming 
sufficient force could be generated, this electromagnetic pump could be used to generate 
samples from a well plate and push them toward the MCE device for analysis (Figure 
5-2). Preliminary work would need to be done to determine the number, placement, and 
current needed to create sufficient pumping force. However, in a similar method using a 
ferrofluid, linear flow rates as high up to 7.4 mm/s (40 mL/min) within a PVC pipe (15.4 
  85 
mm i.d. x 21 mm o.d.) were achieved using 12 A current at 1 kHz when using a 16 
electromagnet array.170 The primary advantage over the HyperCyt method is that droplets 
would not be compressed in the pump, which may cause coalescence or break up. 
Additionally, through use of microfabrication strategies a miniaturized pump could be 
developed allowing integration with existing droplet generation workflows. 
 
 
Figure 5-2. Schematic of electromagnetic fluid pump for segmented flow using magnetic 
ionic liquids (MIL) as the carrier fluid. Several coils of wire would be placed in a series 
along the Teflon tubing (i.e. electromagnets) and energized sequentially to generate a 
traveling magnetic wave. This magnetic wave would drive the MIL and droplets through 
the tubing. 
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Protein-Protein Interaction Screening by Microchip Electrophoresis 
Although the major focus of this thesis was development of analytical methods 
for screening biochemical assays, the general principles (i.e. mobility shift between 
substrate and product) could be applied to alternative screening targets. Within the cell, 
few proteins act independently. Instead, proteins interact as part of large protein 
complexes held together by non-covalent interactions based on intermolecular forces, 
such as hydrostatic or hydrophobic interactions. Through these large interactions, 
collections of proteins can work synergistically to achieve complex cellular functions, 
such as DNA replication, transcription, or metabolism. Therefore, protein-protein 
interactions (PPIs) provide useful targets for disease intervention and drug discovery.171, 
172  
Previously in our group, PPI screening based on electrophoresis has been 
developed for Hsp70-Bag3 interactions.22 Using affinity probe capillary electrophoresis, 
a library of over 3000 molecules was screened against this non-covalent complex (Figure 
5-3). However, throughput was limited to ~220 samples per day and separation efficiency 
was poor due to additional pressure driven flow. The long separation time was due to a 
combination of long detection length and suppression of EOF caused by derivatized 
capillaries (necessary to prevent protein adsorption). To increase the utility, faster 
separations and higher throughput are necessary. 
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Figure 5-3. Affinity probe capillary electrophoresis for monitoring protein-protein 
interactions. One protein (affinity probe) is labeled with a fluorescent tag while the other 
protein is unlabeled. Two peaks are observed in the electropherogram corresponding to 
the labeled protein and the protein complex (labeled protein bound to unlabeled target).22 
Reproduced with permissions from American Chemical Society. 
By adapting the separation to microchip format, shorter separation lengths and 
high voltages could be used to significantly reduce separation time. Additionally, through 
the use of high pH buffer (i.e. 10 mM borate at pH 10) and short separation lengths, 
protein adsorption to channel surfaces could be significantly reduced. Using a glass MCE 
device with 3 cm separation length, a 15 s separation of the free Hsp70 and Hsp70-Bag3 
complex is possible (Figure 5-4A). When injected alone, Alexa Fluor 488-labeled Hsp70 
is detected at 12 s, whereas the migration time shifts to 10 s when Hsp70 complexes with 
Bag3. The addition of unlabeled Hsp70 competes for Bag3 binding resulting in 
observation of both complex and free Hps70 peaks in the electropherogram. To ensure 
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that basic separation conditions do not greatly impact complex formation, Hsp70 was 
incubated with increasing concentrations of Bag3 to determine the binding constant 
(Figure 5-4B). Under these conditions a binding constant of 140 ± 20 nM was calculated 
for Hsp70. Using flow cytometry protein interaction assays (FCPIA), the binding 
constant was reported to be 14 nM. Although the large difference could be caused by use 
of high pH buffers, a binding study with lower Hsp70 concentration is necessary to 
accurately determine the binding constant for on chip analysis. 
 
 
Figure 5-4. Protein-protein interaction monitoring using affinity probe microchip 
electrophoresis. A) Unbound Hsp70 (blue trace) can be separated from the protein 
complex (red trace) using a 14 second separation. Competition between labeled and 
unlabeled Hsp70 for Bag3 binding leads to both peaks in the electropherogram (black 
trace). B) Binding assay plot for 0.5 µM Hsp70 with Bag3. Binding constant is 140 nM. 
Reducing separation time from 6.5 min to 15 s increased throughput 26-fold 
relative to the initial CE assay. Additionally, complicated derivatization methods are not 
required, as protein adsorption was not observed in a glass MCE device when using basic 
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buffers. Preliminary droplet experiments suggest that sample introduction is not affected 
by protein-rich samples though more work is needed to determine long-term stability.  
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Coupling Droplet Samples to Microchip Electrochromatography 
Although zone electrophoresis represents a powerful separation technique for 
many applications, coupling droplet samples to separation techniques (e.g. LC) would 
reduce sample requirements for an even broader range of analytes. However, 
desegmentation of samples prior to analysis by LC, for example, and injection of 
nanoliter aliquots can be difficult. To address this, other separation modes could be 
integrated into the existing microchip system to allow routine analysis of droplet samples. 
In the existing droplet-MCE device, electroosmotic flow is used to move samples around 
the microchip without the need for valves or external pressure pumps. By maintaining 
EOF pumping and incorporating a packed chromatographic bed or entangled polymer 
solution on-chip, electrochromatography or gel electrophoresis separations could be 
possible (Figure 5-5). 
 For microchip electrochromatography (MEC), replacing the existing separation 
channel (3 µm x 36 µm) with a deeper and wider channel (50 µm x 100 µm) would allow 
for packing with 5-10 µm stationary phase. The bed could be packed through the chip 
outlet with the narrow channels for sample handling serving as a weir to constrain the 
particle bed. After packing, a UV curable frit could be formed near the channel outlet to 
prevent bed movement during analysis. Coupling droplet samples to MEC opens of a 
number of potential applications. For the analysis of in vivo neurochemical samples, our 
group has previously reported using LC-MS with benzoyl chloride sample derivatization 
or MCE with naphthalene-2,3-dicarboxaldehyde derivatization for analysis of dialysate 
samples.173 Analysis by LC-MS typically requires several microliters of sample, limiting 
temporal resolution. Analysis by CE is much faster, but is limited to analysis of amino 
  91 
acid neurotransmitters due to detection limits. (See Appendix C for improvements to 
neurotransmitter separations by MCE by controlling separation channel parameters.)  To 
improve temporal resolution, samples could be segmented as nanoliter volume droplets 
and analyzed on chip by CEC to increase the number of analytes that could be monitored 
relative to previous CE-based separations.75, 126  
 A similar modification of the microchip could be used to analyze protein samples 
by gel electrophoresis with greatly reduced sample requirements. Using a UV-cured gel 
phase, an entangled polymer bed could be formed selectively within the separation 
channel. With the other solutions operating under free solution conditions, sample could 
be quickly directed toward the flow gated injection cross and injected onto the bed for 
separation. Our group has pioneered work in microscale western blotting using capillary 
and microchip electrophoresis.174, 175 Although each electrokinetic injection requires only 
a few hundred picoliters of sample, filling the sample reservoir typically requires at least 
5-10 µL of sample. Additionally, manually filling sample reservoirs is time consuming 
and limits sample throughput. To address these challenges, samples could be introduced 
to the microchip as a series of droplets and sequentially injected onto the gel bed for 
separation, reducing sample requirements to several nanoliters and allowing higher 
throughput. 
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Figure 5-5. Microfluidic device for capillary electrochromatography (CEC) or gel 
electrophoresis (CGE) from droplet samples. A larger bore channel to accommodate 
entangled polymer beds or stationary phase replaces the narrow bore electrophoresis 
channel. The injection cross, with physical weir, and detection point with UV frit are 
shown in enlarged regions. 
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APPENDICES 
Appendix A 
Fabrication Strategies for Deep Etching of Glass Substrates 
Fabrication of droplet analysis devices requires deep etching (>75 µm) of 
capillary insertion channels to facilitate sample transfer. In order to maintain feature 
fidelity, several substrate optimizations were required. The standard substrate used for 
glass devices consists of a 0.7-1.1 mm glass slide coated with 530 nm of low reflectivity 
chromium and 500 nm of AZ1505 photoresist. During etching both coatings are required 
to prevent wholesale etching of the substrate. Without chrome present, photoresist 
adhesion to glass is poor and delamination occurs within several minutes of etching. 
Likewise, without photoresist present to protect the chrome layer, hydrofluoric acid will 
rapidly etch away the chrome layer leaving a pitted and uneven surface on the substrate. 
When etching very deep channels using substrates with both coatings prepared by 
our glass supplier (Telic Company), some devices would come out with rough channel 
features that were highly anisotropic in etching pattern (i.e. more horizontally etched than 
vertically etched) making them unusable (Figure A-1A). This phenomenon was dubbed 
‘rough etching’ and occurred in 25 to 40 percent of devices and varied greatly from batch 
to batch. The high random occurrence and etching anisotropy suggested that chrome 
adhesion was poor leading to flaking during long etches. Cleaning and polishing glass 
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substrates prior to sputter chrome was tested, but proved unsuccessful at mitigating the 
issue. 
After much experimentation and step-by-step investigation of the substrates, 
chrome layer stress induced by sputter coating was identified as the issue. To relive the 
stress and improve etching, glass slides were coated with chrome and annealed at 310 °C 
for 3 hr prior to spinning AZ1505 photoresist. Under these conditions, etching up to 200 
µm deep features was possible without issues related to chrome layer adhesion (Figure A-
1B). Using the same substrate (prior to annealing), rough etching is observed. Although 
the effect is most noticeable when etching deep features, significantly surface roughness 
was observed even for shallow features (<10 µm). Therefore, it is recommended to 
anneal any glass slides used for deep features or in cases when high feature fidelity is 
required.  
 
 
Figure A-1. Images of rough (A) and smooth (B) etching of glass slides. In the rough 
etched image, the channel is much wider due to anisotropic etching and the walls are not 
smooth. After annealing, isotropic etching occurs and channels have smooth surfaces. 
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Because the manufacturer is unable to anneal the chrome layer prior to shipment, 
substrates should be ordered without photoresist and annealed in lab. After annealing the 
chrome layer, photoresist must be applied using the following procedure (Figure A-2). 
Hexamethyldisilazane, an adhesion promoter, is applied to the substrate using a spin 
coater at 500 RPM for 15 s. AZ1505 photoresist is dispensed to evenly cover the entire 
substrate and a 500 nm layer is formed by spinning at 4000 RPM for 45 s. After spinning, 
substrates are placed on a hot plate at 100 °C for 50 s to soft-bake the photoresist. (Note: 
It is crucial that a hot plate be used for all baking steps, as contact heat is required for 
even solvent evaporation.) If an oven will be used, optimization is necessary. After 
cooling, substrates are exposed through a photomask for ~9 s and photoresist is 
developed (AZ726 developer) for 40 s with gentle shaking. Uncovered chrome is etched 
in CR1A chrome etching for 2 min to expose glass for HF etching. Substrates should be 
rinsed in deionized water, dried under nitrogen, and placed on a hot plate at 115 °C for 1 
min to set photoresist. At this point, taping and HF etching can proceed as normal. 
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Figure A-2. Overview of fabrication process for deep feature etching with high fidelity. 
Chrome coated substrates are annealed at 310 °C for 3 hr prior to spin coating 500 nm of 
AZ1505 resist. After soft baking, photomask pattern is transferred by UV exposure. 
Photoresist is developed and exposed chrome is etched to reveal glass substrate for HF 
etching. 
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Appendix B 
Inhibitor Structure and Potency from SIRT5 Screening 
Compound Structure IC50 (µM) Curve Fit 
Fulvestrant 
 
2.6 0.9055 
Antimycin A 
 
90 0.6418 
Thyroxine 
 
2.2 0.9569 
Probucol 
 
1.6 0.9685 
Closantel 
 
2.7 0.9350 
Balsalazide 
 
3.9 0.9214 
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Methacylcine 
 
3.6 0.9281 
Anthralin 
 
0.1 0.9176 
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Appendix C 
Effect of Channel Geometry on Separation Speed and Efficiency 
 In electrophoretic separations, efficiency is a measure of separation quality and 
can be determined from the following equation: 
𝑁𝑁 = 𝑡𝑡𝑚𝑚𝑚𝑚𝑚𝑚2
𝜎𝜎𝑚𝑚𝑜𝑜𝑚𝑚
2  
in which tmig is analyte migration time and σtot is the total zone variance from all sources 
of band broadening. Of these, Joule heating can significantly reduce separation efficiency 
through the formation of temperature gradients caused by resistive heating of the 
separation buffer under high electric field. These temperature gradients lead to 
differences in mobility within the analytes zone causing broader peaks. To mitigate these 
effects, narrow bore capillaries are used to improve heat dissipation due to increased 
surface area-to-volume ratio. Within microchips, heat dissipation primarily occurs 
through the top and bottom of the microchannel where the substrate is thinnest and to a 
lesser extend out the sides of the channel. Historically, capillary-based separations have 
higher efficiency (>500,000 theoretical plates) due to more efficient heat dissipation 
allowing application of higher electric fields. On the other hand, microchip separations, 
have separation efficiency less than 250,000 theoretical plates. 
 To investigate the effect of channel cross section, which impacts surface area-to-
volume ratio, devices with channel depths of 6 µm and 3 µm were used to separate a set 
of derivatized amino acids. In both cases, the channels are thin and wide to provide more 
surface area on the top and bottom of the channel for heat dissipation. For a 6 µm x 42 
µm channel, the surface area-to-volume ratio is 0.37 and a 3 µm x 36 µm channel has a 
ratio of 0.72 allowing for better heat dissipation. When the same electric field is applied – 
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1,100 V/cm – the current is 40 percent lower on a 3 µm chip significantly reducing joule 
heating. This is evidenced in the electropherograms for each condition. With 6 µm 
channels, separation efficiency is 200,000 theoretical plates and plate height is 550 nm. 
Baseline resolution is not achieved between all analytes and only moderate separation is 
observed between D- and L-aspartate (Figure C-1A). In contrast, when channel height is 
reduced to 3 µm, efficiency improves to ~400,000 plates with a plate height of 275 nm. 
Baseline resolution is observed between all analytes, including chiral separation of D- and 
L-aspartate (Figure C-1B). Qualitatively, this can be observed as much sharper peaks for 
all analytes compared to deep channels. Further reduction in channel cross-section (2 µm 
x 34 µm) resulted in reduced current but separation efficiency was not improved and 
microchannels were easily clogged. 
 
 
Figure C-1. Reduction in channel depth from 6 µm (A) to 3 µm (B) results in 2-fold 
improvement to separation efficiency as measured by theoretical plates. For both devices, 
applied electric field was 1,100 V/cm, LIF detection occurred at 11.1 cm, and 
background electrolyte was 10 mM sodium tetraborate, pH 10 with 0.9 mM 
hydroxyproply-β-cylcodextran. 
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 Although separation efficiency is greatly improved, separation time remains 
relatively long (15 seconds with overlapping injections) limiting analysis throughput. CE 
theory states that separation length can be reduced, under the same applied voltage, 
without sacrificing separation efficiency and resulting in faster separations. To test this, 
devices with 3 µm deep channels were fabricated with 12 cm and 4 cm separation 
lengths. The same voltage was applied resulting in higher electric field on the 4 cm 
device (2,800 V/cm). On the shorter chip, separation time was reduced to 2 seconds using 
an overlapped injection (Figure C-2). Separation efficiency, measured in theoretical 
plates, was reduced to 130,000; however, plate height was 230 nm, which is similar to 
chips with longer channels. The reduced efficiency could be attributed to over-injection 
caused by the high electric field and software limit of 10 ms injections. With independent 
control of injection voltage, it is anticipated that separation efficiency could be further 
improved by reducing injection volume. 
 
 
Figure C-2. Reduction in channel length from 12 cm (A) to 4 cm (B) while maintaining 
the same applied voltage results in short separation times with similar separation 
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efficiency. Electric field was 1,100 V/cm for A and 2,800 V/cm for B with the same 
background electrolyte as in Figure B-1. 
 These improvements move microchip electrophoresis significantly closer to 
traditional capillary separations in terms of efficiency, when comparing relatively long 
channels. By reducing separation length, a fast and efficient separation of labeled 
neurotransmitters is possible. This opens up a number of possibilities for in vivo chemical 
monitoring by allowing multi-analyte detection without sacrificing temporal resolution. 
Several challenges remain with using these separations. Injection control software to 
allow shorter injections or lower field during injection is necessary to improve efficiency. 
Additionally, achieving high electric field on chip requires application of very high 
voltages (-12 kV and + 8 kV) and arcing is common. To improve long-term operation at 
high voltages, an improved electrode design with better insulation is necessary. 
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